picture
RJR-logo

About | BLOGS | Portfolio | Misc | Recommended | What's New | What's Hot

About | BLOGS | Portfolio | Misc | Recommended | What's New | What's Hot

icon

Bibliography Options Menu

icon
QUERY RUN:
21 Nov 2026 at 01:37
HITS:
52587
PAGE OPTIONS:
Hide Abstracts   |   Hide Additional Links
NOTE:
Long bibliographies are displayed in blocks of 100 citations at a time. At the end of each block there is an option to load the next block.

Bibliography on: Alzheimer Disease — Current Literature

RJR-3x

Robert J. Robbins is a biologist, an educator, a science administrator, a publisher, an information technologist, and an IT leader and manager who specializes in advancing biomedical knowledge and supporting education through the application of information technology. More About:  RJR | OUR TEAM | OUR SERVICES | THIS WEBSITE

RJR: Recommended Bibliography 21 Nov 2026 at 01:37 Created: 

Alzheimer Disease — Current Literature

Alzheimer's disease is an irreversible, progressive brain disorder that slowly destroys memory and thinking skills, and eventually the ability to carry out the simplest tasks. In most people with Alzheimer's, symptoms first appear in their mid-60s. Alzheimer's is the most common cause of dementia among older adults. Dementia is the loss of cognitive functioning — thinking, remembering, and reasoning — and behavioral abilities to such an extent that it interferes with a person's daily life and activities. Dementia ranges in severity from the mildest stage, when it is just beginning to affect a person's functioning, to the most severe stage, when the person must depend completely on others for basic activities of daily living. Scientists don't yet fully understand what causes Alzheimer's disease in most people. There is a genetic component to some cases of early-onset Alzheimer's disease. Late-onset Alzheimer's arises from a complex series of brain changes that occur over decades. The causes probably include a combination of genetic, environmental, and lifestyle factors. The importance of any one of these factors in increasing or decreasing the risk of developing Alzheimer's may differ from person to person. This bibliography runs a generic query on "Alzheimer" and then restricts the results to papers published in or after 2017.

Created with PubMed® Query: 2024:2026[dp] AND ( alzheimer*[TIAB] ) NOT pmcbook NOT ispreviousversion

Citations The Papers (from PubMed®)

-->

RevDate: 2026-11-19

Syamala S, P Joseph (2026)

Protective relation between influenza vaccination and subjective cognitive decline in older US adults.

Annals of geriatric medicine and research pii:agmr.26.0054 [Epub ahead of print].

BACKGROUND: Subjective cognitive decline (SCD) has been shown to be associated with increased risk of dementia and Alzheimer's disease. Some studies have reported an inverse association between influenza vaccination and dementia; however, the relationship between vaccination and SCD is not known. In this context, we examined the association between influenza vaccination and SCD in a large, multiethnic sample of older US adults.

METHODS: Cross-sectional study of n=5,729 older adults (aged ≥65 years) who participated in the 2021-2022 Behavioral Risk Factor Surveillance System (BRFSS) and completed the BRFSS Cognitive Decline Module questions. Influenza vaccination status during the past 12 months was ascertained from the questionnaire, and the main outcome of interest was SCD.

RESULTS: SCD was present among 43.4% of older US adults aged ≥65 years. The weighted prevalence of SCD was 51.7% among those without influenza vaccination vs. 39.3% among those with influenza vaccination (P<0.001). Compared to those without influenza vaccination (reference category), the multivariable-adjusted odds ratio (95% confidence interval) of SCD was 0.67 (0.53-0.86; P=0.001) among those with influenza vaccination. The inverse association was present consistently in subgroup analyses by sex, age, education, and body mass index, and persisted after adjusting for potential confounders.

CONCLUSION: In this nationally representative sample of older US adults, we found that influenza vaccination showed a significant inverse association with SCD, though a causal effect cannot be inferred due to the cross-sectional design.

RevDate: 2026-11-19

Marcal T, D Sohmer (2026)

Preparing geriatric nurses for a new era in Alzheimer's care.

Geriatric nursing (New York, N.Y.) pii:S0197-4572(26)00642-7 [Epub ahead of print].

Recent advances in Alzheimer's diagnosis and treatment are changing the care needs of older adults and creating new responsibilities for geriatric nurses. Blood-based biomarkers and disease-modifying therapies offer new opportunities for earlier diagnosis and treatment, while increasing demands for patient education, care coordination, and monitoring. This NICHE column examines the evolving role of geriatric nurses across the Alzheimer's care journey and highlights the importance of workforce support, empowerment, and capacity building to translate scientific advances into person-centered care.

RevDate: 2026-11-19

Yang G, Ghimire DJ, Jones RN, et al (2026)

Measuring cognition in Nepal: Factor structure of the Nepal Harmonized Cognitive Assessment Protocol (N-HCAP).

International psychogeriatrics pii:S1041-6102(26)00150-X [Epub ahead of print].

Reliable and valid cognitive assessment instruments are needed to study cognitive aging and dementia in Nepal. To address this need, the Harmonized Cognitive Assessment Protocol was adapted for Nepal (N-HCAP). We aimed to evaluate the factor structure, measurement precision, and criterion validity of the N-HCAP. We analyzed N-HCAP data from 3051 participants aged ≥ 50 in the Chitwan Valley Family Study-Study on Cognition and Aging in Nepal. Using confirmatory factor analysis, we evaluated five theoretically driven domains: orientation, memory, executive functioning, language, and visuospatial. We also evaluated a hierarchical measurement model in which the five domains loaded on a higher-order factor. We examined factor score distributions, reliability, and evaluated criterion validity through associations with age and years of school. Participants had a mean age of 64.0 years, 51.6% were female, and 48.1% had no formal schooling. Domain-specific models showed adequate to good fit (comparative fit index [CFI] = 0.95-1.00, root mean square error of approximation [RMSEA] = 0.02-0.06, standardized root mean square residual [SRMR] = 0.01-0.08). The hierarchical model also showed good fit (CFI = 0.96, RMSEA = 0.03, SRMR = 0.052). Measurement precision was generally adequate (≥0.70) but varied across domains and performance levels. All factor scores were negatively correlated with age (r = -0.47 to -0.31) and positively correlated with years of school (r = 0.36-0.62). Findings support the measurement structure and preliminary criterion validity of the N-HCAP, consistent with findings from other HCAP studies. Future research should evaluate clinical validity.

RevDate: 2026-11-19

Patel S (2026)

Ins and Outs of Lysosomal Ca[2+]: Recent Advances.

Cold Spring Harbor perspectives in biology pii:cshperspect.a041785 [Epub ahead of print].

Lysosomes are multifunctional organelles that store and release calcium ions (Ca[2+]), a key second messenger. Two-pore channels (TPCs) and members of the transient receptor potential (TRP) mucolipin (TRPML) subfamily are the principal lysosomal Ca[2+] release channels, but how Ca[2+] is taken up by lysosomes is less clear. TPCs have emerged as unusual ion channels that are able to dramatically switch their ion selectivity from a Ca[2+]-permeable state to a more Na[+]-selective state to differentially control cell-wide Ca[2+] signals and lysosomal function in an agonist-selective manner. Long-sought accessory proteins that confer sensitivity of these channels to the Ca[2+] mobilizing messenger nicotinic acid adenine dinucleotide phosphate (NAADP) have been identified as JPT2 and Lsm12. Functional roles for TPCs in trafficking both inwardly (phagocytosis) as well as outwardly (hormone/inflammatory mediator secretion and adhesion molecule presentation) have been resolved-roles likely linked to the actions of TPCs at membrane contact sites between the endolysosomal system and the endoplasmic reticulum (ER). Gain-of-function in TPC2 by mutation, or by loss of a negative channel regulation (through TMEM63A), causes pigmentation and pancreatic dysfunction, respectively. Inhibiting TPCs by molecular or chemical means, in particular with tetrandrine (for which analog-bound structures exist), is proving beneficial in models of Alzheimer disease, Parkinson's disease, stroke, and melanoma. Select activation of TPC2 by new "mode-switching" agonists appears to be equally beneficial in correcting lysosomal storage disorders and Parkinson's disease. Like TPCs, TRP mucolipins are activated by the phosphoinositide PI(3,5)P2 More recently discovered endogenous TRP mucolipin activators include pressure and PI(3)P. Also, like TPCs, TRP mucolipins appear functionally coupled to Ca[2+] channels on the sarcoplasmic reticulum with a surprising role for TRPML1 in generating ryanodine receptor-dependent subcellular Ca[2+] signals underpinning smooth muscle contractility. Insight into regulation of autophagy by TRP mucolipins accrues; we also now know that activation of TRPML1 results in direct Ca[2+] transfer from lysosomes to mitochondria at contact sites between the two organelles, and that this communication is disrupted in Mucolipidosis type IV, as well as in models of other neurogenerative diseases. TRP mucolipins are implicated in lung dysfunction and cancer, with the first identification of cancer-causing mutations in TRPML3. TRP mucolipin agonists have now been used successfully to correct phenotypes in a number of disease models, and agonist, as well as antagonist-bound structures, are providing new atomic insight into channel workings. The molecular basis for lysosomal Ca[2+] uptake continues to be actively investigated. Candidates include the Ca[2+] transporter TMEM165, the mutation of which is known to cause congenital disorders of glycosylation, and pumps such as ATP13A2 and those found typically on the ER.

RevDate: 2026-11-19
CmpDate: 2026-11-19

Mohiuddin M (2026)

Psychobiotics and the Microbiota-Gut-Brain Axis: Mechanistic Insights, Multi-Omics Advances, and Therapeutic Potential in Mental and Systemic Disorders.

Journal of food science, 91(11):.

Common mental illnesses, such as anxiety, depression, and neurodegenerative diseases, are increasing worldwide, and there is increasing evidence that their pathogenesis is associated with gut microbiota dysbiosis and disruption of the microbiota-gut-brain axis (MGBA). Nevertheless, there is a lack of mechanistic understanding and clinical translation of psychobiotics. This review consolidates the results of preclinical, clinical, and multi-omics research to assess the role of psychobiotics, such as prebiotics, probiotics, synbiotics, and postbiotics, in regulating MGBA pathways, including endocrine, immune, neural, and metabolic pathways, along with developments in metabolite detection and microbial profiling. Psychobiotics normalize the intestinal microbial composition, increase the intestinal barrier integrity, and balance neuroinflammation. They modulate the levels of major neurotransmitters (dopamine, serotonin, γ-aminobutyric acid) and suppress hyperactivity of the hypothalamic-pituitary-adrenal (HPA) axis. There is growing evidence showing their therapeutic efficacy in gastrointestinal, metabolic, autoimmune, and neuropsychiatric diseases, including anxiety, depression, and Alzheimer's and Parkinson's diseases. Synergistic effects with neuro-nutrition and physical activity further enhance cognitive function and neuroplasticity. Psychobiotics provide a mechanism-based approach to address interconnected pathways of the MGBA, which is an exciting addition to traditional treatments with an excellent safety profile. Precision psychobiotic intervention and translation of multi-omics approaches into clinical practice require standardized and large-scale clinical trials as well as integration of these methods.

RevDate: 2026-11-19
CmpDate: 2026-11-19

Crestol A, van der Meer D, Parker N, et al (2026)

Sex differences in polygenic risk for sex-biased brain disorders: Associations with diagnostic status and brain age gap.

Translational psychiatry, 16(1):.

Biological sex influences the prevalence and progression of several brain disorders, yet it remains unclear whether genetic risk interacts with sex in relation to case-control status or brain health. Using data from up to 220 836 females and 187 651 males in the UK Biobank (aged 39-81), we assessed how sex and polygenic risk scores (PRSs) for major depressive disorder (PRSMDD), Alzheimer's disease (PRSAD), schizophrenia (PRSSCZ), and Parkinson's disease (PRSPD) relate to case-control status and MRI-derived brain age gap (BAG) as a proxy of brain health. We tested for sex differences in PRSs and performed regression analyses examining associations between sex, PRSs, and both outcomes. We then compared models with sex-pooled or sex-specific PRSs to explore whether sex-specific PRSs improve predictive accuracy. PRSSCZ was higher in females, while no other PRSs differed by sex. A significant PRSAD-by-sex interaction revealed weaker associations with AD case-control status in males than females. Sex-pooled models outperformed sex-specific models for case-control status, apart from PRSAD, where the female-only PRSAD model outperformed the sex-pooled model. No sex-by-PRS interactions were significantly associated with BAG. However, male sex, higher PRSMDD, higher PRSAD, and lower PRSPD were associated with higher BAG, indicative of an older brain age. BAG model performance did not differ between sex-pooled and sex-specific PRS models. In summary, while sex-specific PRSs currently offer limited value over sex-pooled scores, the superior performance of the female-specific PRSAD model suggests that the value of sex-specific PRSs will likely grow with increased statistical power. Link to preregistration and preprint: https://osf.io/a8pt2/ .

RevDate: 2026-11-19
CmpDate: 2026-11-19

Pieperhoff L, Tranfa M, Arunachalam P, et al (2026)

AMYPAD-PNHS: A Pan-European, Multi-Site & Multimodal MRI Dataset of Older Adults Without Dementia.

Scientific data, 13(1):.

The Amyloid Imaging to Prevent Alzheimer's Disease Prognostic and Natural History Study (AMYPAD-PNHS) multimodal magnetic resonance imaging (MRI) dataset provides open-access longitudinal MRI data of 2759 cognitively normal or mild cognitive impairment individuals, encompassing (micro-)structural, physiological, and functional MRI sequences from 10 European parent cohorts. Processed and raw images, and image-derived (endo-)phenotypes, are organized in Brain Imaging Data Structure (BIDS) standards and accessible upon request, to enhance generalizability and comparability between future neuroimaging studies. This dataset supports preclinical Alzheimer's disease (AD) and aging-related research by enabling robust multimodal analyses of neurodegeneration, microvascular pathology, and structural and functional connectivity changes, facilitating advanced investigations into preclinical AD mechanisms, informing early intervention strategies and allowing reproducible and centralized neuroimaging (endo-)phenotyping.

RevDate: 2026-11-19
CmpDate: 2026-11-19

Amato LG, Scheijbeler E, van Nifterick A, et al (2026)

Predicting Alzheimer progression using EEG-based digital twins.

NPJ digital medicine, 9(1):.

Early and accurate prognosis of Alzheimer's disease (AD) remains limited by current biomarkers, which are often invasive, require expensive equipment, or fail to predict individual trajectories of cognitive decline. In this study, we evaluated the Digital Alzheimer's Disease Diagnosis (DADD) model, a digital twin framework that extracts neurodegeneration-related digital biomarkers from non-invasive recordings such as electroencephalography (EEG), mapping early functional neural alterations to latent parameters linked to structural AD mechanisms. DADD was applied to a cohort of 459 participants with Subjective Cognitive Decline (SCD) or Mild Cognitive Impairment (MCI), evaluating its performance against established AD biomarkers like APOE genotype, magnetic resonance imaging (MRI) and cerebrospinal fluid (CSF) markers in predicting prognostic outcomes over a 10-year follow-up. Digital biomarkers demonstrated strong prognostic value, predicting participants who converted at follow-up, significantly outperforming standard EEG metrics. They also robustly forecast both risk and timing of clinical conversion, matching the performance of established AD biomarkers and even outperforming them in SCD participants. Moreover, combining established AD biomarkers with digital biomarkers led to a significant increase in prognostic accuracy. DADD represents a robust clinical tool, enabling scalable, affordable, non-invasive AD detection and prognostic stratification across diverse clinical settings.

RevDate: 2026-11-19

Morales-Delgado R, Álvarez-Villalobos NA, Merino-Varela C, et al (2026)

Real world evidence of second-generation antipsychotics for the management of behavioral and psychological symptoms of dementia: a systematic review and meta-analysis.

Psychopharmacology [Epub ahead of print].

PURPOSE: This is the first systematic review synthesizing exclusively real-world evidence about the efficacy, acceptability, and tolerability of the most used Second-generation antipsychotics (SGAs) for the management of Behavioral and psychological symptoms of dementia (BPSD).

METHODS: Observational or quasi-experimental real-world studies were included involving participants with a mean age of > 50 years and an Alzheimer Disease, vascular dementia or mixed dementia diagnosis with BPSD. Interventions were SGAs. Suitable comparators were placebo, other SGAs or no-treatment. Studies with or without a control group were eligible. The primary outcomes were efficacy, acceptability and tolerability of SGAs for the management of BPSD. Certainty of the evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework. PROSPERO (CRD420251143630).

RESULTS: 17 studies were included, encompassing 7,748 participants. Of the evaluated SGAs, only risperidone (k = 5 studies, n = 1469) and quetiapine (k = 4 studies, n = 89) had sufficient real-world evidence for pre-post analyses. Two studies provided direct comparisons between risperidone and olanzapine. The pooled analysis showed no significant difference between risperidone and olanzapine on efficacy (SMD = - 0.19; 95% CI [ - 1.72, 1.34], I[2] = 0%). BPSD appear to improve in pre-post studies with risperidone (SMD = - 1.36; 95% CI [ - 1.67, - 1.06], I[2] = 82.1%), but not with quetiapine (MD: - 15.17; 95% CI [-32.18 to 1.84]; I[2] = 89.7%). Quality of evidence was evaluated as very low on all outcomes.

CONCLUSION: While evidence suggests that risperidone is associated with significant management of BPSD in routine clinical practice, quetiapine appears to show limited efficacy and lower acceptability; although apparent inefficacy may probably depend on small sample size. Despite lower discontinuation rates than those reported in clinical trials, the risks of EPS, falls, and mortality support the need for careful monitoring and individualized risk-benefit assessment. The very low quality of the evidence demands careful interpretation of findings.

RevDate: 2026-11-19
CmpDate: 2026-11-20

Valibeygi A, Zareian F, Tavassoli A, et al (2026)

Anacyclus pyrethrum extract improves spatial memory and cognition in a rat model of Alzheimer's disease.

BMC complementary medicine and therapies, 26(1):.

BACKGROUND: Alzheimer's disease (AD) is the most prevalent dementia disorder, causing significant disability in the affected patients. This disorder is currently considered incurable. In this study, we aim to use the hydroalcoholic extract of Anacyclus Pyrethrum (AP) as a potential treatment for cognitive dysfunction in a rat model of AD induced with intracerebroventricular injection of Amyloid-beta 1-42.

METHODS: Forty-eight rats were randomly assigned to six groups (n = 8): control, sham, Aβ-injected (5 µg, ICV), and treatment groups receiving AP extract (500 mg/kg/day), donepezil (0.3 mg/kg/day), or their combination for 14 days following AD induction. Spatial memory was assessed using the Morris Water Maze (MWM), and brain metabolic changes were evaluated using positron emission tomography (PET). Histopathological analyses were also performed.

RESULTS: Positron emission tomography (PET) scan results supported the successful induction of Aβ‑related metabolic changes. MWM results showed that treatment groups significantly decreased swim distance to the platform, increased time spent in the target quadrant, and reduced mean distance from the former platform location. AP-treated, donepezil, and combination therapies demonstrated significantly better performance over time.

CONCLUSION: Oral administration of the hydroalcoholic extract of AP was associated with improved memory performance in a rat model of AD. These results call for more research to assess the AP extract's ability to reduce cognitive impairments in AD.

RevDate: 2026-11-20
CmpDate: 2026-11-20

Muñoz-Castro C, Healey MA, Noori A, et al (2026)

GFAP upregulation by astrocytes attenuates tau neurofibrillary tangle pathology in a mouse model of tauopathy.

Molecular neurodegeneration, 21(1):.

BACKGROUND: The upregulation of the intermediate filament glial fibrillary acidic protein (GFAP) by reactive astrocytes has been traditionally assigned structural functions such as the shaping of astrocyte morphology and the formation of the glial scar. However, in vitro studies have also implicated GFAP in chaperone-mediated autophagy and endolysosomal trafficking. Here we hypothesized a role of GFAP in proteostasis in neurodegenerative proteinopathies. Specifically, we tested whether GFAP upregulation by reactive astrocytes helps control phospho-tau (pTau) neurofibrillary tangle burden in vivo.

METHODS: We investigated the interactome of GFAP in human control and AD brains via co-immunoprecipitation (co-IP) followed by mass spectrometry. We also overexpressed GFAP in the astrocytes of THY-Tau22 mice using a viral transfer approach and characterized downstream effects on astrocyte phenotype, pTau burden, and neurodegenerative measures by combining immunohistochemistry, biochemistry, RNA-sequencing, and co-IP/mass spectrometry.

RESULTS: We show that the interactome of GFAP immunoprecipitated from human control and AD brains is unexpectedly enriched in proteostasis effectors. Overexpressing GFAP in astrocytes of THY-Tau22 mice reduced hippocampal pTau neurofibrillary tangle burden, increased presynaptic marker levels, and modulated neuronal c-Fos expression, with more pronounced effects in female mice. Mechanistically, transcriptomic analysis revealed an induction of genes involved in extracellular matrix and small GTPases mediating cytoskeleton dynamics, whereas co-IP/mass spectrometry revealed an extensive network of proteostasis-related interactors, including components of endocytosis/macropinocytosis, lysosomal autophagy, heat shock protein response, and the ubiquitin-proteasome system.

CONCLUSIONS: These findings challenge the conventional view of GFAP as a mere scaffold protein of the astrocyte cytoskeleton and suggest a novel role of GFAP in proteostasis with potential neuroprotective effects.

RevDate: 2026-11-19
CmpDate: 2026-11-20

D'Agostini M, Zhao W, Dahl MJ, et al (2026)

Do Interindividual Differences Matter? Testing Differences in Locus Coeruleus MRI Contrast as a Function of Age, Sex, and Body Mass Index.

Psychophysiology, 63(11):.

The locus coeruleus (LC) plays a key role in cognitive decline and Alzheimer's disease (AD). Investigating demographic differences in the LC is important because these differences may contribute to lifelong AD risk. Noninvasive MRI assessments of LC contrast are associated with cognitive performance and are hypothesized to reflect the nucleus's structural integrity. Age and sex differences in LC MRI contrast have been documented. Nonetheless, results are mixed, and most previous studies are hampered by small samples and a lack of standardization in the inspection of data quality and registration accuracy. In this cross-sectional study, we aim to investigate differences in LC MRI contrast as a function of demographic variables associated with increased AD prevalence: age, sex, and body mass index (BMI). We will pool fast spin echo (FSE) scans of young (age: 18-33) and older adults (age: 55-90) from eight datasets collected in three sites (N = 663). A semiautomatic pipeline will be adopted to register FSE scans to MNI space and segment the LC using a high-confidence LC mask. To maximize reproducibility, we will evaluate data quality using markers of in-scanner motion and nonphysiological noise, and we will rely on a standardized visual inspection to assess registration accuracy. We will run linear mixed models, including a nested random effect of acquisition batch (i.e., datasets grouped by study and site) to account for variability in LC MRI contrast driven by non-biological factors (e.g., hardware). We expect that LC contrast is positively associated with chronological age in young adults but negatively associated in older adults. On average, it is expected to be higher in older adults and in females. We will explore sex-by-age-group effects and BMI differences in LC MRI contrast. This study offers a reproducible foundation for understanding demographic variation in LC MRI contrast.

RevDate: 2026-11-20
CmpDate: 2026-11-20

Boeriu AI, Gu T, Fulton-Howard B, et al (2026)

Ancestry-specific effects of apolipoprotein E on Alzheimer's disease endophenotypes.

Alzheimer's & dementia : the journal of the Alzheimer's Association, 22(11):.

INTRODUCTION: Apolipoprotein E (APOE) *ε4 is the strongest genetic risk factor for Alzheimer's disease (AD), yet its effect varies across ancestral populations. As plasma biomarkers increasingly inform AD diagnosis, failure to account for both APOE genotype and genetic ancestry could lead to diagnostic misclassification.

METHODS: In 2,733 participants from the Health and Aging Brain Study-Health Disparities (HABS-HD), we evaluated whether genetically-inferred ancestry modifies APOE associations with AD endophenotypes. Regression models were applied across three frameworks: ancestry-stratified analyses, compositional modeling of global ancestry, and local ancestry analyses at the APOE locus.

RESULTS: APOE ε4+ was associated with higher pTau217 and pTau181, lower Aβ42/Aβ40, and worse global cognition (Clinical Dementia Rating - Sum of Boxes [CDR-SB]), significant within ancestry groups after false discovery rate (FDR) correction. The ε4+ effect on pTau217 was ∼2.5-fold larger in EUR-like than AFR-like participants.

DISCUSSION: African ancestry attenuates APOE*ε4+ associations with pTau217, highlighting the need to consider both APOE genotype and ancestry in biomarker-based AD evaluations.

RevDate: 2026-11-20
CmpDate: 2026-11-20

Burns C, Bergner AL, Mulhern M, et al (2026)

Exploring Predictive Genetic Testing Practices Across Adult-Onset Neurodegenerative Disorders.

Journal of genetic counseling, 35(6):.

A predictive genetic testing protocol for Huntington disease (HD) has been published and utilized since 1989. The current guideline recommends an intake call, pre-test genetic counseling, neurological examination, mental health assessment, results disclosure, and post-test follow up. Predictive testing is now available for other common adult-onset neurodegenerative disorders (AOND), including Alzheimer's disease, amyotrophic lateral sclerosis, spinocerebellar ataxia, frontotemporal dementia, Parkinson's disease, prion disease, and CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy), yet similar protocols for most of these conditions have not been developed. It is hypothesized that the HD protocol is guiding predictive testing across AONDs, but this has not been formally evaluated. This exploratory, cross-sectional study surveyed genetic counselors (GCs) regarding their predictive testing practices. A total of 70 responses were received; 66 were included in demographic and other characteristic analysis, and 59 were included in practice descriptive analysis. GCs reported an average of 1.89 predictive cases per month and primarily operated within a neurology clinic (52/66, 79%). A total of 215 predictive testing practices were collected from the 59 respondents. Pre-test GC appointments (99%, n = 213) and a results disclosure session (100%, n = 215) were consistently incorporated in current practices. Over half of respondents utilized a mental health assessment (63%, n = 136) and structured follow-up after results are disclosed (58%, n = 124). Less than half of respondents utilized an intake call (48%, n = 104) and neurological examination (38%, n = 81). This study found that a vast majority of pre-test GC appointments were documented in the electronic medical record (207/213, 97%) and billed using insurance (164/213, 77%). GCs were reported as the most frequent healthcare professional involved in the assessment of mental health (118/136, 97%). Overall, these findings suggest that GCs are adapting the current HD predictive testing protocol similarly across AONDs. These findings provide insight into the current practices of predictive testing for AONDs in the absence of formal condition-specific guidelines.

RevDate: 2026-11-20

Arslan B, Simrén J, Palm K, et al (2026)

Analytical validation of an in-house CSF neurogranin assay for clinical use.

Clinical chemistry and laboratory medicine [Epub ahead of print].

OBJECTIVES: Synaptic dysfunction is an early and central feature of Alzheimer's disease (AD), and cerebrospinal fluid (CSF) neurogranin (Ng) has emerged as a promising biomarker reflecting synaptic pathology. However, despite its increasing use in research, comprehensive analytical and clinical validation supporting its routine clinical use remains limited.

METHODS: We developed an updated version of an in-house CSF Ng enzyme-linked immunosorbent assay (UGOT-Ng) and performed a full analytical validation, including precision, selectivity, measurement range, dilution linearity, interference, and sample stability. Method comparison with a previous assay version and instrument comparability were also assessed. A distribution-derived upper threshold was established using a large set of prospectively measured routine clinical samples. Finally, the associations between CSF Ng concentrations and core AD biomarkers were examined in a large retrospective dataset.

RESULTS: The assay demonstrated acceptable analytical performance, with good repeatability and intermediate precision across the evaluated concentration levels. The measurement range was established at 38-1,200 ng/L, with satisfactory dilution linearity and minimal interference from blood contamination. CSF Ng showed high stability under various preanalytical conditions. Distribution-derived analysis in amyloid-negative clinical samples yielded an upper limit of 390 ng/L. In clinical samples, CSF Ng correlated strongly with total tau and phosphorylated tau, while associations with Aβ42/40 were weaker and largely driven by differences between amyloid-positive and -negative individuals.

CONCLUSIONS: This study provides a comprehensive analytical validation of an in-house CSF Ng assay, supporting its implementation in a routine clinical laboratory. CSF Ng was strongly associated with CSF total tau and phosphorylated tau, supporting its relationship with tau-associated neuronal and synaptic pathology in AD. However, the strength of these correlations also raises the possibility that CSF Ng provides information that overlaps with established tau biomarkers. Further studies should therefore determine whether Ng offers incremental diagnostic or prognostic value, identifies biologically distinct patient subgroups, or improves the monitoring of synaptic dysfunction beyond currently available biomarkers.

RevDate: 2026-11-20
CmpDate: 2026-11-20

Chen C, Xu H, Rennie A, et al (2026)

Biomarker-informed differences in treatment-associated cognitive decline in dementia with Lewy bodies.

Alzheimer's & dementia : the journal of the Alzheimer's Association, 22(11):.

INTRODUCTION: Alzheimer's disease (AD) co-pathology is common in dementia with Lewy bodies (DLB) and has been linked to worse clinical outcomes. Whether AD biomarker status influences cognitive trajectories and treatment-associated cognitive trajectories in DLB remains unclear.

METHODS: We conducted a retrospective cohort study by linking the Swedish Registry for Cognitive/Dementia Disorders (SveDem) with cerebrospinal fluid (CSF) biomarker data. Participants were individuals with incident DLB diagnosed between 2010 and 2020 who had CSF amyloid-β42/amyloid-β40 (Aβ42/40) or Aβ42/phosphorylated tau (p-tau) measurements and longitudinal Mini-Mental State Examination (MMSE) assessments during follow-up. Linear mixed-effects models incorporating inverse probability of treatment and censoring weighting estimated cognitive trajectories according to AD biomarker status and antidementia treatment.

RESULTS: Among 360 participants (mean age 73.3 years; 33.9% women), 196 (54.4%) were AD biomarker-positive. AD biomarker-positive participants exhibited faster cognitive decline than biomarker-negative participants, with an additional decline of 0.80 MMSE points per year (95% confidence interval [CI], -1.17 to -0.43). Overall, cholinesterase inhibitor (ChEI) use was associated with slower cognitive decline than no treatment, whereas associations for memantine were less consistent. In biomarker-stratified analyses, ChEI use was associated with slower decline among AD biomarker-positive participants but not among biomarker-negative participants. Formal interaction analyses indicated that treatment-associated differences in MMSE change varied according to AD biomarker status.

DISCUSSION: AD biomarker positivity identifies a subgroup of individuals with DLB at higher risk of accelerated cognitive decline. Treatment-associated cognitive trajectories also differed according to AD biomarker status; however, these observational treatment findings require cautious interpretation and confirmation in prospective biomarker-stratified studies.

RevDate: 2026-11-20
CmpDate: 2026-11-20

Chang F, Z Duren (2026)

Contrasting within-donor gene covariation identifies disease-associated cells and genes in case-control single-cell studies.

bioRxiv : the preprint server for biology pii:2026.11.06.764894.

In case-control single-cell studies, disease often affects only a subset of cells of a given type within each patient. Comparing all cells from patients with all cells from control donors therefore dilutes disease signals, while donor variation and recorded or unrecorded batch effects can be confounded with disease status. We present IDC (Identification of Disease-associated Cells), which uses this cellular heterogeneity as signal. A mixture of affected and unaffected cells creates coordinated variation among disease-associated genes within each patient, whereas shifts shared by all cells of a donor leave this within-donor covariance unchanged. IDC therefore contrasts within-donor gene-gene covariance between patients and controls to learn disease-associated expression programs without batch labels, then applies positive-unlabeled learning to score each cell's disease-like state and estimate each donor's disease burden. IDC also computes, in closed form, gene contribution scores and leave-gene-out cell scores that exclude each tested gene, enabling within-donor differential expression testing and cross-donor meta-analysis without retraining. In simulations, IDC identified affected cells and estimated donor burden more accurately than deep generative and label-refinement methods, remained robust to strong unrecorded batch effects, and detected differentially expressed genes more sensitively than case-control pseudobulk methods while controlling false discoveries. In human pancreatic islets and prefrontal cortex, disease burden in held-out donors separated type 2 diabetes (T2D) from non-diabetic donors in beta cells, and late-stage Alzheimer's disease (AD) from non-AD donors in astrocytes and inhibitory neurons, while placing prediabetic and early-AD donors at intermediate levels. Genes with the highest IDC contribution scores were more strongly enriched for the KEGG T2D and AD pathways than case-control pseudobulk rankings, and within-donor testing revealed coordinated metabolic, cell-adhesion and synaptic changes along the inferred disease axis.

RevDate: 2026-11-20
CmpDate: 2026-11-20

Bhoopal B, Fitzgerald RW, Gollapelli KK, et al (2026)

First-in-class [ [18] F]-PET radiotracers for GPR39: A platform for noninvasive target engagement imaging in vivo.

bioRxiv : the preprint server for biology pii:2026.11.06.764940.

Disrupted zinc homeostasis is a hallmark of Alzheimer's disease. As a key zinc-sensing receptor, GPR39, a G-protein coupled receptor is implicated in neurodegeneration, vascular regulation, and neuropsychiatric disorders, represents an emerging target for molecular imaging. However, the lack of suitable positron emission tomography (PET) radiotracers has limited GPR39 in vivo characterization. Quantitative assessment of GPR39 levels in vivo helps in understanding its role in physiology and pathology. This will facilitate the development of targeted therapeutics and enable real-time monitoring of treatment response in clinical settings. This study introduces [ [18] F]GPR39-2.1 as a PET radiotracer specificity towards GPR39. [ [18] F]GPR39-2.1 exhibited excellent serum stability with negligible radio-metabolite formation. In vitro cell uptake studies showed reduced tracer uptake (55-70%) upon pharmacological blockade. PET imaging demonstrated rapid brain uptake and efficient with blood-brain barrier penetration, followed by gradual washout. Blockade studies in rats revealed significant reductions in brain uptake (up to ∼90%, **** p <0.0001), consistent across multiple brain regions. Receptor specificity was further validated in GPR39 knockout mice, which exhibited reduced brain uptake of 76% (** p <0.002) and 90% (*** p <0.0002) in both PET imaging and biodistribution studies, respectively. Moreover, significantly lower brain uptake observed in 5xFAD transgenic mice (PET imaging: 40%, *** p <0.0002 and biodistribution: 77%, ** p <0.002) indicates sensitivity of [ [18] F]GPR39-2.1 to disease-associated changes of GPR39. Biodistribution analysis revealed favorable pharmacokinetics. Autoradiography studies further confirmed the specificity of [ [18] F]GPR39-2.1 towards GPR39, corroborating PET imaging and biodistribution studies. These findings establish [ [18] F]GPR39-2.1 as a highly specific, stable, and brain-penetrant PET radiotracer for imaging GPR39 in vivo . This work supports the utility of [ [18] F]GPR39-2.1 as a noninvasive molecular imaging agent for neurological and systemic diseases associated with GPR39 dysregulation. Overall, this work establishes a translational framework for investigating GPR39 biology and facilitates its clinical translation as a diagnostic and therapeutic target through [ [18] F]GPR39-2.1.

RevDate: 2026-11-20
CmpDate: 2026-11-20

Sgourdou P, Vrettos N, Hoxha K, et al (2026)

SilencioMA: A single compound that targets both MAPT and APP as a potential disease modifying therapeutic for Alzheimer's Disease.

bioRxiv : the preprint server for biology pii:2026.11.09.765491.

Alzheimer's Disease (AD) is the most common age-related neurodegenerative disease and the leading cause of dementia worldwide. AD pathogenesis involves aggregation of amyloid-beta (Aβ), produced from amyloidogenic proteolytic processing of Amyloid Precursor Protein (APP), and accumulation of misfolded, pathological tau (Microtubule Associated Protein Tau, MAPT). Current efforts focus on developing disease modifying therapeutics (DMTs) against single targets: Aβ or tau. However, DMTs that concurrently target both tau and Aβ are likely to have the greatest impact since they target both culprits of AD pathogenesis. Here we describe the development of SilencioMA, a single compound that targets both MAPT and APP messenger RNAs (mRNAs) based on silencing connected interfering oligonucleotides against MAPT and APP. Cerebrospinal fluid (CSF) administration of SilencioMA reduces Aβ and tau and pathology after a single intracerebroventricular injection in 5XFAD/PS19 mice, an animal model of severe amyloidosis and tauopathy. SilencioMA does not rely on lipid nanoparticles or lipophilic conjugates for CSF administration. At the same time its modular design permits conjugation of ligands that facilitate transcytosis through the blood brain barrier, allowing systemic administration. Our findings provide proof-of-concept for a strategy that targets the dual Aβ and tau pathologies of AD, and establishes a compelling foundation for further development of SilencioMA as a next-generation DMT for AD.

RevDate: 2026-11-20
CmpDate: 2026-11-20

Oveisgharan S, Longo S, Yang J, et al (2026)

Histological characteristics of the quadriceps muscle and their associations with gait in older adults.

medRxiv : the preprint server for health sciences pii:2026.11.10.26367782.

BACKGROUND/OBJECTIVE: There is a paucity of data about muscle morphology in aging adults. We quantified histologic features of the quadriceps muscle and examined their associations with gait function and physical activity in community-dwelling older adults.

METHODS: Participants were from the Rush Memory and Aging Project. Postmortem sections of the quadriceps muscles were examined by immunohistochemistry using antibodies against myosin heavy chain, and histological characteristics of the quadriceps muscles were derived through images quantifications and segmentations. In addition, brain sections were assessed for collection of Alzheimer's disease and related dementias pathologies. Before death, participants' physical activity was objectively measured through wearing an accelerometer sensor for 10 days, and gait function was quantified by walking 8 feet and turning 360° twice. Linear regressions and compositional analyses were used for analyzing data.

RESULTS: Postmortem quadriceps was examined in 236 decedents (mean age at death was 91.7±6.0 years, and 71.6% (n=169) were females. On average, 44.7% (SD=19.5) of the muscle fibers were type I and 54.2% (SD=19.4) were type II, and 40.6% (SD=13.0) and 21.9% (12.9) of the quadriceps muscle area were composed of type I and II muscle fibers, respectively. In compositional analyses, male sex (estimate=0.303, SE=0.126, p=0.016) and more physical activity (estimate=0.118, SE=0.059, p=0.045) were associated with larger quadriceps muscle areas with type II muscle fibers, which were related to better gait (estimate=-0.049, SE=0.021, p=0.021). Quadriceps muscle composition explained an additional 3.2% of gait's variance beyond the 5.8% variance explained by Alzheimer's disease and related dementias brain pathologies.

CONCLUSION: Quadriceps muscles having larger areas with type II muscle fibers were associated with more physical activity and better gait function in aging adults. Elucidating the molecular mechanisms underlying these associations are critical for developing new therapies.

RevDate: 2026-11-20
CmpDate: 2026-11-20

Lohman T, Joyce J, Quiring M, et al (2026)

Beat-to-beat blood pressure variability and Alzheimer's disease pathophysiology.

medRxiv : the preprint server for health sciences pii:2026.11.10.26367476.

INTRODUCTION: Elevated blood pressure variability (BPV) is predictive of Alzheimer's disease neuropathologic change observed with AD biomarkers. However, prior studies have largely focused on visit-to-visit BPV, which may be influenced by antihypertensive medication adherence and other external factors. Few studies have investigated beat-to-beat BPV, a reliable and direct measure of cardiovascular and autonomic function relevant to AD.

METHODS: Independently living older adults (N=132) were recruited from the community. Participants underwent continuous blood pressure monitoring and venipuncture. Plasma p- Tau 217 , p-Tau 181 , GFAP, NfL, and amyloid-β 42/40 ratio were assessed. Linear regression examined the relationship between beat-to-beat systolic BPV and plasma AD biomarkers with and without adjustment for age, sex, systolic blood pressure, and apolipoprotein E4 (APOE4) carrier status.

RESULTS: Elevated beat-to-beat BPV was associated with elevated plasma p-Tau 217 (β=0.32, p=0.008), plasma p-Tau 181 (β=0.22, p=0.05), and plasma GFAP (β=0.41, p=0.00001). Elevated BPV was not associated with plasma amyloid-β 42/40 ratio or plasma NfL.

DISCUSSION: Increased beat-to-beat BPV is associated with increased Core 1 T 1 biomarkers of phosphorylated and secreted AD tau in blood plasma (i.e., pTau 217 , pTau 181), but not with amyloid-β 42/40 ratio, a biomarker more exclusively indexing cerebral amyloid retention alone. Elevated BPV was also associated with higher plasma GFAP, a marker of astrocyte reactivity. These findings are consistent with prior studies relating visit-to-visit BPV to AD biomarkers, suggesting that intrinsic cardiovascular and/or autonomic factors underlie links between BPV and AD.

RevDate: 2026-11-20
CmpDate: 2026-11-20

Plubell D, Merrihew G, Park J, et al (2026)

Peptide-centric proteomics reveals molecular subtypes of sporadic Alzheimer's disease.

bioRxiv : the preprint server for biology pii:2026.11.12.766321.

Alzheimer's disease (AD) is a complex, age-related disease that continues to increase in incidence worldwide. Although some cases are caused by known pathogenic mutations, the majority of cases are sporadic, with uncertain etiology and commonly complicated by comorbid diseases. To better understand the molecular landscape of AD we constructed a unique brain sample set free from neuropathologic comorbidities. This cohort consists of autosomal dominant AD dementia, sporadic AD dementia, cognitively normal individuals with high AD neuropathologic change - a condition called resilient to AD, and cognitively normal cases with no or minimal AD neuropathologic change. Through quantitative mass spectrometry proteomics we obtain measures of peptides mapping to Aβ and to tau, capturing differences in the histopathologic burden of disease. Correlations of these peptide abundance differences within sporadic AD dementia cases in the superior and medial temporal gyrus indicate the presence of two separate sporadic AD phenotypes. Additional differences are characterized at a peptide level between sporadic AD dementia and autosomal dominant AD dementia in the inferior parietal lobe and caudate nucleus. These findings indicate both shared and distinct molecular features in AD influenced by cause and age of onset of disease.

RevDate: 2026-11-20
CmpDate: 2026-11-20

Vazquez-Hidalgo E, Mews M, Gomez L, et al (2026)

Genetic ancestry influences the relative expression of ancestral haplotypes within admixed individuals.

bioRxiv : the preprint server for biology pii:2026.11.11.765740.

Allele-specific expression (ASE) reflects differences between the two haplotypes a person carries, but most ASE studies have been done in European-descent samples. Admixed individuals carry haplotypes from different ancestral backgrounds within the same cell, which allows ancestry effects on regulation to be measured directly. We integrated phased whole-blood RNA-seq with local ancestry inference in 779 participants from the MAGENTA cohort, including non-Hispanic White, African American, Caribbean Hispanic, and Peruvian individuals. Higher West African (YRI) ancestry proportion was associated with more ASE-positive genes per person, and the association remained after adjusting for age, sex, Alzheimer's disease status, APOE genotype, and the number of heterozygous genes. Peruvian ancestry showed no significant association. A gene-level test of imbalance across population groups found 2,053 of 15,008 genes with significant differences, including the major histocompatibility complex in all four groups. A genome-wide scan of 2,213 1 Mb windows compared people carrying two haplotypes of different ancestries with those carrying two of the same ancestry. It identified 52 non-redundant loci that replicated across all four population groups, containing 201, 60, and 110 ancestry-associated genes under the CEU, YRI, and PEL reference baselines. A haplotype-resolved directional analysis showed no genome-wide advantage for either ancestry. It found locus-specific dominance at 11 loci, and only chr8:2-3 Mb (CSMD1) showed the same direction in more than one population group. Genetic ancestry therefore shapes allelic regulation at global, gene, and locus scales.

RevDate: 2026-11-20
CmpDate: 2026-11-20

Mustafa Y, Yang Y, Mews M, et al (2026)

Peripheral Immune Cell Shifts Associated With Alzheimer's Disease Vary in Multi-Ancestry Cohorts.

bioRxiv : the preprint server for biology pii:2026.11.11.765813.

BACKGROUND: Alzheimer's disease (AD) is heavily influenced by immune system dysregulation, yet the role of peripheral immune processes-and how these vary across ethnicities-remains understudied.

OBJECTIVE: To investigate ancestry-specific immune alterations in AD by profiling peripheral immune cell proportions using high-resolution deconvolution of whole blood RNA-sequencing data, characterizing disease associated cell types, and identifying enriched biological pathways.

METHODS: We analyzed whole blood RNA-seq data from non-Hispanic White (NHW), African American (AA), Caribbean Hispanic (CariHISP), and Peruvian (PERU) individuals, balanced between AD cases and cognitively normal controls. Immune cell proportions were estimated using CIBERSORTx and compared using linear models (propeller R package) adjusted for age, sex, and APOE genotypes in case-control models. Cell-type-specific differential expression was performed using CARseq, and pathway enrichment analyses performed using MSigDB gene sets.

RESULTS: Baseline immune composition differed substantially across cohorts for multiple innate and adaptive cell types. In a multi-ethnic AD versus control analysis, eight cell types reached FDR significance: AD was associated with decreased proportions naïve B cells, CD56dim NK cells, B cells, intermediate monocyte I, and double-negative T cells, alongside significant expansion in neutrophils and non-classical monocytes. Interaction analyses revealed heterogeneous group-specific effects, with the broadest shifts in AA and CariHISP. Pathway enrichment indicated shared heme metabolism, interferon, and oxidative phosphorylation programs across groups, with distinct emphases: broad, strong heme metabolism enrichment and the highest oxidative phosphorylation signal (in myeloid populations) in AA; MYC targets in naïve B cells and eosinophils in CariHISP; dendritic cell-and T follicular helper cell-centered interferon, inflammatory, and proliferative programs in NHW; and TGF-β and apoptosis signatures, unique to PERU, alongside the broadest cell-type coverage.

CONCLUSIONS: Peripheral immune dysregulation in AD is characterized by depletion of lymphoid and intermediate monocyte populations with concurrent neutrophil and non-classical monocyte expansion, and these patterns vary meaningfully by ancestry. These findings underscore the need for population-informed biomarkers and therapeutic strategies in AD.

RevDate: 2026-11-20
CmpDate: 2026-11-20

Sánchez-Puelles C, Hernández-Vivanco A, Grieco A, et al (2026)

E2F4 gene therapy reverses established synaptic and cognitive deficits and remodels learning-associated signaling in Alzheimer's disease mice.

bioRxiv : the preprint server for biology pii:2026.11.13.766444.

Alzheimer's disease (AD) causes progressive synaptic dysfunction, neurodegeneration, and cognitive decline, yet strategies capable of reversing established deficits remain limited. Here, we show that neuronal expression of a p38MAPK phosphorylation-resistant human E2F4 variant (hE2F4DN), delivered by adeno-associated virus, restores hippocampal long-term potentiation and memory in homozygous 5xFAD mice after functional impairment is established. Treatment also reduces amyloid-β and phospho-tau pathology and prevents hippocampal neuronal loss. Integrated proteomic and phosphoproteomic analyses reveal remodeling of metabolic, redox, neuroimmune, synaptic-vesicle, and GSK3β-associated signaling pathways. Following contextual fear conditioning, hE2F4DN-treated mice exhibit broader learning-associated synaptic proteomic signatures and distinct phosphoregulatory responses involving synaptic machinery. These findings demonstrate that E2F4 gene therapy can reverse established synaptic and cognitive deficits while preserving neuronal integrity and reshaping molecular responses to learning, identifying E2F4 phosphorylation as a potential therapeutic target for advanced AD states.

RevDate: 2026-11-20
CmpDate: 2026-11-20

Esmonde C, Raulin AC, Parsons T, et al (2026)

APOE4 Alters the Inflammatory and Metabolic Properties of Extracellular Vesicles of Induced Pluripotent Stem Cell-derived Astrocytes and Mesenchymal Stromal Cells.

Research square pii:rs.3.rs-11104163.

Background Apolipoprotein E (APOE) is a lipid transporter whose variant, APOE4 , is the strongest genetic predictor of Alzheimer's disease development. APOE's role as a lipid transporter is disrupted with E4 due to differences in its binding affinity, altering APOE's preferred lipid substrate. This alters the cholesterol homeostasis of neural cells such as astrocytes, leading to lipid droplet formation, a driver of neuroinflammation. In addition, APOE has been identified as a cargo protein carried within extracellular vesicles (EVs), including exosomes, suggesting EVs play a role in regulating neural lipid metabolism. However, the extent and further results of APOE disruption of EV excretion and cargo are not well-established. Methods This study seeks to identify differences in EV secretion and bioactivity between APOE3 and APOE4 genotypes in various cell types and the role they play in Alzheimer's disease pathogenesis. Human pluripotent potent stem cell-derived astrocytes (iASs) and mesenchymal stromal cells (iMSCs) with homozygous APOE3 and homozygous APOE44 cellswere derived and the secreted EVs were characterized. Results Our results indicate that EV secretion was comparable in APOE3 and APOE4 cells, although decreased expression of the endosomal sorting complex required for transport (ESCRT) dependent and independent genes in APOE4 cells was observed. When treating THP-1 cells, an innate inflammatory capability is observed across cell types in APOE4 EVs, increasing the levels of NF-κB activation significantly compared to untreated controls. Quantitative lipidomics revealed increased levels of total lipid and lipid classes involved in the mediation of lipid stress in APOE4 EVs. In addition, lipids involved in EV biogenesis are dysregulated. KEGG analysis showed upregulation of functional pathways of interest in Alzheimer's Disease progression, including efferocytosis, choline metabolism, and bile acid synthesis. Conclusions Our results suggest that APOE4 may affect the lipid cargo of the EVs, which is hypothesized to be a result of endosomal trafficking via interruptions in both ESCRT dependent and independent biogenesis pathways. Furthermore, disrupted lipid metabolism in APOE4 could affect ESCRT-independent EV formation. APOE4 derived EVs have innate inflammatory properties that are exacerbated in the presence of excess fatty acid. This study paves the way for understanding the role of EVs in mediating inflammation and lipid metabolism in APOE4 related Alzheimer's disease.

RevDate: 2026-11-20
CmpDate: 2026-11-20

Fouladivanda M, Iraji A, Phadikar S, et al (2026)

DECODE: DEcomposition of COupled and DEcoupled Brain States: Separating Structure-Coupled and Structure-Decoupled Functional Organization in Alzheimer's Disease.

bioRxiv : the preprint server for biology pii:2026.11.09.765343.

Brain functional activity emerges within an underlying structural scaffold. While structural network connectivity provides a relatively stable anatomical backbone for large-scale communication, functional interactions are high-dimensional and temporally dynamic, forming recurrent patterns that can be represented in a latent space of transient functional states. Yet, how these transient functional states are organized and the extent to which they remain constrained by structural network connectivity or become relatively decoupled from structural organization over time remain poorly understood. To address this gap, we introduce DECODE (DEcomposition of COupled and DEcoupled Brain States), a data-driven latent-space framework that uses independent component analysis (ICA) and multimodal data to decompose resting-state dynamic functional network connectivity into a lower-dimensional representation of transient functional states. These states capture temporally varying structure-coupled and structure-decoupled patterns using diffusion MRI-derived structural network connectivity priors. Structure-coupled states reflect functional configurations more strongly anchored to major structural motifs, whereas structure-decoupled states represent configurations less constrained by the identified structural organization, while potentially remaining within structurally defined dynamical bounds. DECODE identifies reproducible structure-coupled and structure-decoupled states, with mean squared error reconstruction of dynamic information < 0.1 and adjusted R [2] = 0.4. Applied to Alzheimer's disease (AD), DECODE revealed stronger group differences (FDR-corrected p-value 0.05) in both connectivity organization and temporal dynamics for decoupled states. These findings suggest that functional states less constrained by identified structural organization may be more vulnerable to AD-related disruption, whereas structure-coupled states may be relatively preserved. More broadly, DECODE provides a reproducible and generalizable framework for quantifying how functional dynamics are shaped by, or diverge from, structural organization by incorporating a latent representation of the structural connectome as an informative prior. Our findings established structural and functional alignment variation by distinguishing dynamic functional patterns closely coupled with structure from those that deviate from it.

RevDate: 2026-11-20
CmpDate: 2026-11-20

Zadok M, Calderon N, Wald Y, et al (2026)

LLM Representations Rival Traditional Predictors and Enhance Multimodal Prediction of APOE4 and Aβ-Burden.

medRxiv : the preprint server for health sciences pii:2026.11.09.26367620.

Spontaneous language offers a scalable, non-invasive approach for identifying biological indicators of preclinical Alzheimer's disease (AD). We examined prediction of APOE4 carrier status and cerebral amyloid-β (Aβ) burden using Cookie Theft picture-descriptions from two cohorts, including Hebrew- and English-speakers (IRAP, N=134; and WRAP, N=1,541). Aβ burden was classified across lowest-quartile, median, and highest-quartile cutoffs, capturing accumulation below conventional amyloid-positivity thresholds. We compared embeddings from pretrained large language models (LLMs) to standard cognitive test scores, reflecting current clinical assessment, and theory-driven linguistic features, reflecting traditional language analysis. Embedding-based models achieve the highest F1 among constituent models in five of eight tasks for APOE4 status and global Aβ. High prediction disagreement suggests complementary signals between approaches. An any-positive ensemble significantly outperforms every constituent model and a prior-informed random baseline across all eight tasks, and is also significantly superior to all constituent models in 21 of 24 regional Aβ tasks. These findings highlight the complementarity of LLM-based, theory-driven, and cognitive measures for predicting AD-related genetic risk and pathology, and supports development of early screening approaches.

RevDate: 2026-11-20
CmpDate: 2026-11-20

Li H, Fassini A, Aygar S, et al (2026)

Naturally Occurring Soluble Aβ Oligomers Induce State-Dependent Hippocampal Circuit Dysfunction in Nontransgenic Mice.

Research square pii:rs.3.rs-11234037.

Amyloid-beta (Aβ) plaques are a hallmark of Alzheimer's Disease (AD), but the modest cognitive benefit of anti-amyloid antibodies despite plaque clearance implicates plaque-independent mechanisms in disease progression. Aβ oligomers (AβOs), a toxic soluble species, disrupt synapses, but their effects on hippocampal circuit function in vivo remain unclear. We tested whether naturally occurring AβOs are sufficient to disrupt hippocampal circuit function independent of plaques in nontransgenic mice, infusing wild-type culture medium (WtCM), Tg2576-derived culture medium containing naturally occurring human AβOs (TgCM), or Aβ-immunodepleted TgCM into CA1. We recorded hippocampal calcium activity and local field potentials as mice explored a linear track and during post-learning quiet wakefulness. During exploratory behavior, TgCM impaired theta-gamma coupling versus WtCM, without affecting running, calcium activity, or place cells. During quiet wakefulness, TgCM reduced calcium activity versus WtCM, without a detectable effect on reactivation, delta oscillations, or sharp wave ripples. Aβ depletion prevented both effects. These results suggest that AβO-induced circuit disruption depends on behavioral state, implicating distinct vulnerabilities in encoding and offline processing. Because these effects occurred in nontransgenic hippocampus without amyloid plaques or chronic transgene expression, soluble AβOs are sufficient to disrupt memory-relevant circuit function and represent a therapeutic target upstream of plaque clearance.

RevDate: 2026-11-20
CmpDate: 2026-11-20

Satyadev N, Gogineni V, Corriveau-Lecavalier N, et al (2026)

A shared slowing axis and phenotype-specific rhythms link clinical EEG to FDG-PET dementia phenotypes.

bioRxiv : the preprint server for biology pii:2026.11.09.764237.

Early and accurate identification of neurodegenerative disorders has notable implications for treatment and quality of life. Whereas neuroimaging-based biomarkers can accurately identify neurodegenerative subtypes, EEG represents a low-cost alternative that could expand access to dementia care. Here, we investigated whether six data-driven EEG latent factors, derived by nonnegative tensor decomposition of clinical EEGs, differ systematically across FDG-PET-defined neurodegenerative phenotypes. In 455 patients with EEG and FDG-PET acquired within one year of each other, factor expression was compared across 14 diagnostic classes assigned by StateViewer, a validated artificial intelligence framework for FDG-PET interpretation. To separate disease-general severity from phenotype-specific topography, each factor was also regressed on a subject-level slowing index. Finally, we related the factors to regional FDG uptake and to neuropsychological performance (n = 98) and assessed their potential utility for single-subject classification. Four factors reflecting neurophysiological oscillations (posterior alpha, Rolandic beta, frontotemporal delta-theta and posterior theta-slow alpha) varied significantly across phenotypes, with attenuation of faster and augmentation of slower rhythms most pronounced in dementia with Lewy bodies (DLB), dysexecutive Alzheimer disease (AD) and posterior cortical atrophy, whereas factors dominated by eye-movement and muscle artifact showed no robust phenotypic association. Alpha and beta effects were largely attributable to overall slowing, whereas posterior theta-slow alpha became more phenotype-specific after adjustment (eta-squared 0.082 to 0.147), dissociating the Alzheimer disease spectrum from frontotemporal syndromes. The slowing index tracked with an FDG-PET pattern highly associated with DLB across the cohort, irrespective of assigned phenotype (r = 0.51, P < 0.001). Consistent with a model in which dementia phenotypes reflect altered hippocampal-neocortical oscillatory coupling (stochastic latent oscillatory diffusion), frontotemporal delta-theta tracked a limbocortical axis of metabolic pattern expression, rising with neocortical and falling with limbic-predominant involvement, independent of overall slowing and phenotype. Each factor mapped onto a distinct metabolic topography, with frontotemporal delta-theta resembling Alzheimer-type hypometabolism and posterior theta-slow alpha the medial occipital hypometabolism of DLB. In terms of neuropsychological performance, Rolandic beta was associated with executive functions, and frontotemporal delta-theta with memory, visuospatial and global performance. Using these four factors alone, an exploratory logistic regression classifier separated cognitively unimpaired participants from DLB, posterior cortical atrophy, typical AD, and dysexecutive AD (area under the curve > 0.8) but poorly discriminated frontotemporal dementia phenotypes canonically associated with 4-repeat tau. Thus, data-driven decomposition of clinical EEG separates oscillatory activity from artifact into factors that track metabolic phenotype, regional metabolism and cognition, capturing both overall slowing and phenotype-specific patterns. This work informs the further development of scalable, biology-informed EEG-based phenotyping of neurodegenerative disease.

RevDate: 2026-11-20
CmpDate: 2026-11-20

Johnson NR, Beham J, Sillau S, et al (2026)

Imipramine binds to amyloid-β and extends the survival of Alzheimer's disease patients.

bioRxiv : the preprint server for biology pii:2026.10.28.762584.

BACKGROUND: Apolipoprotein E (apoE) plays numerous roles in the pathogenic pathway to Alzheimer's disease (AD). We previously performed a high-throughput screen and identified the antidepressant imipramine as an inhibitor of the interaction between apoE and amyloid-β (Aβ). We also found that imipramine use to treat depression in AD patients was associated with better Mini-Mental State Exam (MMSE) scores. Here we studied the mechanisms by which imipramine inhibits the AD pathogenic pathway and investigated its effect on mortality in AD patients.

METHODS: Nuclear magnetic resonance spectroscopy was used to characterize the interaction between imipramine and Aβ monomers. Human induced pluripotent stem cell (hiPSC)-derived AD cerebral organoids (COs) and transgenic AD rats treated with imipramine underwent neuropathological evaluation, while rat learning and memory were assessed in the Morris Water Maze. AD patient mortality in the National Alzheimer's Coordinating Center's database was analyzed by Kaplan-Meier and Cox proportional hazards models.

RESULTS: Imipramine inhibits the apoE-Aβ interaction by binding directly to Aβ monomers. Imipramine reduces Aβ accumulation and neuronal cell loss in AD COs. Imipramine-treated female AD rats had enhanced reference memory and increased hippocampal cellularity and cholinergic neurotransmission. AD patients prescribed imipramine had reduced all-cause mortality over 10 years relative to those prescribed other tricyclic antidepressants (TCA), non-TCA antidepressants, or no antidepressants.

CONCLUSIONS: The findings support the conclusions that: a) the mechanism by which apoE confers risk for AD is by catalyzing the polymerization of Aβ into neurotoxic species, b) targeting apoE is a promising, underappreciated strategy for the prevention of AD, c) imipramine should be used more frequently to treat depression in AD clinical practice, and d) imipramine should be evaluated in prospective trials, particularly in APOE4 carriers, as a potential method to improve cognition and reduce mortality in AD.

RevDate: 2026-11-20
CmpDate: 2026-11-20

Shemtov SJ, Cacciottolo M, Christensen A, et al (2026)

ApoE isoforms establish distinct antioxidant trajectories across the aging brain.

bioRxiv : the preprint server for biology pii:2026.11.06.765000.

APOE ε4 is the strongest common genetic risk factor for late-onset Alzheimer's disease, but how ApoE isoforms shape physiology before disease remains unclear. Across the ancestral-to-derived ApoE4→ApoE3→ApoE2 sequence, we examined antioxidant regulation during aging. Young humanized ApoE4 mice had lower antioxidant protein abundance and oxidized phospholipid reduction before detectable oxidative damage, yet accumulated lipid peroxidation products with age despite antioxidant remodeling. ApoE4 cells mounted the strongest antioxidant transcriptional response to sulforaphane but accumulated less protein from targets supporting proteostasis, glutathione synthesis and ferroptosis suppression, alongside altered eIF2α signaling and translation kinetics. Antioxidant transcription shifted from an ApoE4 bias in youth toward ApoE2 with age, and adult APOE4-to-APOE2 switching redirected expression in astrocytes and microglia. Cognitively normal human brains showed regional reductions in nuclear Nrf2 and antioxidant proteins, with transcriptomic analyses supporting context-dependent organization. ApoE isoforms differentially couple stress-responsive transcription to protein output, linking age-dependent antioxidant adaptation to neurodegenerative vulnerability.

RevDate: 2026-11-20
CmpDate: 2026-11-20

Potokiri A, Dwamena AA, H Wang (2026)

Single-nucleus RNA-seq atlas of 5xFAD mouse brain maps cell-type-specific transcriptional disruption and preferential rolipram rescue in VIP interneurons.

bioRxiv : the preprint server for biology pii:2026.11.11.765944.

BACKGROUND: Alzheimer's disease is characterized by progressive synaptic dysfunction and inhibitory circuit disruption across multiple brain cell types. Rolipram, a selective phosphodiesterase 4 (PDE4) inhibitor that elevates intracellular cyclic AMP (cAMP), activates proteasome, and produces robust procognitive effects in AD mouse models. Still, the cell-type-specific transcriptional mechanisms underlying these effects remain uncharacterized.

METHODS: We profiled 29,664 nuclei from 5xFAD and wild-type (WT) mouse right hemisphere across four conditions: WT Vehicle, WT Rolipram, 5xFAD Vehicle, and 5xFAD Rolipram (0.03 mg/kg/day, 30-day subcutaneous osmotic pump) using the Parse Biosciences Evercode WT v3 combinatorial barcoding platform. Nuclei were clustered into 16 annotated cell type populations using Seurat v5. Disease and rescue effects were quantified as log fold changes (LFCs) across all clusters, with Gene Ontology enrichment assessed using clusterProfiler and transcription factor activity inferred using decoupleR.

RESULTS: Disease-associated transcriptional disruption was highly cell-type-specific in its magnitude. Among inhibitory subtypes, VIP/Reln disinhibitory interneurons (n = 149 nuclei) showed the most coherent transcriptional disruption: 289 candidate genes were lower in 5xFAD, with Gene Ontology enrichment concentrated in synapse organization programs, including regulation of synapse structure or activity (padj = 1.5x10^-14, 44 genes), regulation of synapse organization (padj = 1.9x10^-14, 43 genes), and postsynapse organization (padj = 1.1x10^-13, 38 genes). This pathway-level specificity was not reproduced in PVALB or SST interneurons. Astrocytes showed loss of cell-adhesion programs (cell-substrate adhesion padj = 2.4x10^-4, 10 genes). Rolipram rescue was preferential: VIP interneurons yielded 72 true rescue genes and astrocytes yielded 42, with the remaining 14 clusters showing substantially fewer. The cAMP-specific phosphodiesterase Pde7b was disease-context-specifically lower in 5xFAD VIP interneurons (LFC -0.53) and restored by rolipram (LFC +0.54), with WT expression unchanged. decoupleR CREB1 activity inference identified reduced CREB1 activity in 5xFAD VIP interneurons with partial restoration in 5xFAD Rolipram, supporting a stepwise transcriptional cascade in which amyloid pathology reduces cAMP, which suppresses PKA and CREB1 activity. This in turn reduces Pde7b transcription, and rolipram reverses this cascade by blocking cAMP hydrolysis upstream.

CONCLUSION: This single-nucleus atlas provides the first cell-type-resolved characterization of rolipram's transcriptional effects in the 5xFAD brain. VIP disinhibitory interneurons emerge as the most transcriptionally vulnerable inhibitory subtype and the preferential site of rolipram-associated rescue, with the Pde7b/CREB1 signaling axis nominating a tractable, disease-context-specific pharmacological substrate.

RevDate: 2026-11-20
CmpDate: 2026-11-20

Malasala S, Cox N, Sellman G, et al (2026)

Structure-Based Discovery of GTP-Enhanced Rab10 Modulators and Their Effects on Alzheimer's Disease-Relevant Cellular Phenotypes.

bioRxiv : the preprint server for biology pii:2026.10.30.763175.

Rab10-mediated membrane trafficking has been implicated in Alzheimer's disease (AD), but pharmacological tools for investigating its function remain limited. Here, we screened more than 80 million compounds using structure-based virtual screening and prioritized five candidate Rab10 modulators (R1-R5). These compounds exhibited favorable docking scores, stable modeled protein-ligand complexes in molecular dynamics (MD) simulations and predicted acceptable ADME/toxicity profiles. Comparative docking against Rab5, Rab8, and Rab11 predicted preferential interactions with GTP-associated Rab10. R1 and R2 yielded the most favorable Rab10 scores, whereas R3 showed the largest differences between GTP-associated, GDP-containing, and nucleotide-free Rab10 models. Surface plasmon resonance (SPR) revealed micromolar apparent affinities of R1-R4 without added GTP and nanomolar apparent affinities under GTP-containing conditions, generally favoring GTP-bound Rab10 over Rab5. In a cell-based GTP quantification assay, R1 , R2 , R3 , and R5 reduced GTP-bound Rab10, whereas R4 increased it. R3 produced dose- and time-dependent reductions in GTP-bound Rab10 and was selected for functional studies. R3 altered endosomal organization and reduced EEA1 and LAMP1 expressions. In amyloid precursor protein (APP)/presenilin-1-expressing CHO cells, R3 redistributed intracellular APP, reduced APP carboxyl-terminal fragments (APP-CTFs), and decreased enlarged endosome-like structures. In neuronal differentiated PC12 cells, R1 - R3 attenuated NGF withdrawal-induced cytoskeletal disruption and cell death, accompanied by reduced APP-CTF accumulation and tau phosphorylation. These studies highlight novel Rab10 modulators and support their further validation as candidate pharmacological probes for investigating Rab10-associated trafficking and AD-relevant cellular phenotypes.

RevDate: 2026-11-20
CmpDate: 2026-11-20

Chen Y, Khatri U, Xu B, et al (2026)

A Multi-Cohort nnU-Net for White Matter Hyperintensity Segmentation Across 2D and 3D FLAIR Acquisitions.

medRxiv : the preprint server for health sciences pii:2026.11.11.26367656.

BACKGROUND: White matter hyperintensities (WMH) are increasingly pooled across aging, cerebral small vessel disease (CSVD), and dementia cohorts that differ in both disease composition and FLAIR acquisition. Most automated segmentation tools were developed within a narrower range of populations or protocols, and few have been tested for whether segmentation accuracy and error remain consistent across conventional 2D and isotropic 3D FLAIR, or whether the choice of algorithm alters downstream clinical associations.

METHODS: We developed a single nnU-Net model, taking FLAIR and T1-weighted images as inputs, using 460 2D and 3D FLAIR scans from a neurodegenerative cohort (Alzheimer's Disease Neuroimaging Initiative, ADNI), a CSVD-enriched cohort with same-visit paired 2D and 3D FLAIR (Washington University White Matter Ischemic-Hypoxia study, WWISH), and a population-based sample (UK Biobank), holding out 92 scans from 66 participants at the participant-level as an internal test set. We further evaluated the model in an independent ADNI3 3D FLAIR set (n = 25), benchmarking voxel-wise overlap (Dice), volumetric agreement, and lesion-level detection against SHIVA-WMH, segcsvdWMH, and FreeSurfer WMH-SynthSeg, and compared acquisition-specific volume bias in participants with paired 2D and 3D FLAIR. We then compared how WMH volumes from each method predicted incident dementia in cognitively unimpaired adults from ADNI and the Knight Alzheimer Disease Research Center (n = 1,174; 42 incident cases).

RESULTS: In the internal test set, the model achieved a mean Dice of 0.73 (SD 0.10), compared with 0.50, 0.57, and 0.29 for SHIVA-WMH, segcsvdWMH, and WMH-SynthSeg (all FDR-adjusted p < 0.001). Dice was similar on 2D and 3D FLAIR (0.75 vs. 0.71). In WWISH participants imaged with both acquisitions, mean volume bias differed between 2D and 3D scans by 1.8 mL for the model versus 4.7-9.9 mL for the comparators. Advantages were largest in low-burden scans (<5 mL; Dice 0.66 vs. 0.19-0.54) and for lesions of ≤100 voxels (detection 77-87% vs. 14-63%). In ADNI3, the model retained a mean Dice of 0.70 (SD 0.14) without retraining and exceeded all comparators (FDR-adjusted p ≤ 0.002). Model-derived WMH volume was associated with incident dementia beyond clinical covariates (OR per SD 1.40, 95% CI 1.11-1.77; likelihood-ratio p = 0.009; cross-validated AUC 0.71 vs. 0.68), whereas comparator-derived volumes did not significantly improve model fit.

CONCLUSIONS: Training a single model across disease contexts and FLAIR acquisitions yielded WMH segmentation that was similarly accurate on 2D and 3D FLAIR, sensitive to low-burden disease, transferable to an unseen protocol, and clinically informative, supporting its use in multi-cohort, mixed-etiology studies.

KEY POINTS: A single nnU-Net trained across neurodegenerative, cerebral small vessel disease, and population-based cohorts and across 2D and 3D FLAIR outperformed SHIVA-WMH, segcsvdWMH, and WMH-SynthSeg, with the largest gains in low-burden scans and small lesions.In same-visit paired 2D and 3D FLAIR scans, the model's volume bias relative to acquisition-specific reference masks varied less across acquisitions, whereas comparator biases varied with acquisition.Only WMH volume from the model significantly improved model fit for incident dementia beyond clinical covariates, highlighting the potential influence of segmentation algorithm choice on downstream clinical inference.

RevDate: 2026-11-20
CmpDate: 2026-11-20

Clapp Sullivan ML, de la Fuente J, Corley J, et al (2026)

Joint Longitudinal Hazard Modeling Distinguishes Polygenic Effects on Dementia via Premorbid Cognitive Function and Aging-Related Decline.

medRxiv : the preprint server for health sciences pii:2026.11.06.26367441.

Alzheimer's disease and related dementias (AD/ADRD) are clinical disorders characterized by declines in cognitive function to levels at which everyday living is meaningfully impaired. Genetic variants may confer risk for AD/ADRD by way of steeper rates of aging-related cognitive declines or their association with lower premorbid levels of cognitive function that place individuals closer to a clinically severe threshold of cognitive function. We applied joint longitudinal-hazard models to 26-year data from an ancestrally diverse US sample of N = 11,518 adults to estimate effects of multi-ancestry polygenic indices (PGIs) for a range of established risk factors on dementia hazard and the degree they operate via premorbid cognitive function and longitudinal cognitive decline. APOE e4 and PGIs for ADRD, type 2 diabetes, stroke, LDL cholesterol, and hearing loss operated via rate of change, whereas PGIs for educational attainment, cognitive function, physical activity, BMI, smoking, loneliness, schizophrenia, and externalizing were associated with dementia hazard via premorbid differences in cognitive function. Some results varied by continental ancestry. Our implementation of joint longitudinal-hazard models allowed us to distinguish how different genetic risk factors for AD/ADRD operate via degenerative processes that might be therapeutically targeted during later life and via premorbid levels of cognitive function that would require intervention earlier in the life course.

RevDate: 2026-11-20
CmpDate: 2026-11-20

Li Y, Liu Z, Cambi XA, et al (2026)

ROCK inhibitor Ripasudil reduces Alzheimer's pathological proteins and enhances cellular bioenergetics.

bioRxiv : the preprint server for biology pii:2026.11.02.761117.

Rho-associated kinase (ROCK) inhibitors have been explored as an Alzheimer's Disease (AD) therapeutic agent. In this study, we aim to determine the efficacy of a potent ROCK inhibitor, ripasudil, in impacting AD pathological protein tau in mice. The time-course study showed that ripasudil rapidly penetrated mouse brains, reaching maximal concentration half an hour post-injection. To determine the efficacy of ripasudil, we injected App [NL-G-F] knock-in mice with ripasudil at 30 mg/kg and sacrificed them after three hours. We used Tandem Mass Tag labels and compared the proteomic profiles of mouse brains exposed to ripasudil to those exposed to saline. We also treated AD-patient-derived Neural Stem Cells (NSCs) with ripasudil and performed a Seahorse Mito Stress Test to evaluate their impact on mitochondrial activity. Bioinformatics analysis of the proteomic profiles revealed differentially enriched components of chromosome. The Mito Stress Test of NSCs revealed significant increases in basal oxygen consumption, ATP-linked respiration, maximal respiration, and reserve capacity oxygen consumption compared to untreated NSCs. Importantly, we found a significant reduction of Tau and pTau 396 in brains of mice treated with ripasudil. Overall, our findings highlight the feasibility and promise of ROCK inhibitor ripasudil as an AD therapeutic agent.

RevDate: 2026-11-20
CmpDate: 2026-11-20

Zhao W, Guzman SJ, Yoo HJ, et al (2026)

In-vivo MRI of noradrenergic and dopaminergic nuclei predicts future cognition and Alzheimers disease progression.

bioRxiv : the preprint server for biology pii:2026.10.29.762942.

Noradrenergic and dopaminergic nuclei modulate cognition, and post-mortem data indicate they are affected early in the neurodegenerative cascade of Alzheimers disease. We derived in-vivo locus coeruleus (LC) and substantia nigra-ventral tegmental area (SN-VTA) MRI integrity measures from 739 ADNI participants, examined MRI-histology correspondence in individuals with both in-vivo imaging and post-mortem data, and tested whether these measures reflect early MRI-indexed degeneration predicting later cognitive decline. LC and SN-VTA contrast predicted cognitive and behavioral function 10 years later, despite only weak associations with current function. LC- and SN-VTA-associated brain-wide atrophy patterns aligned with PET-derived norepinephrine-transporter and dopamine-receptor maps, respectively. A one-standard-deviation decrease in baseline LC contrast was associated with 84% higher five-year odds of MCI-to-AD progression, and predictive effects of the catecholaminergic nuclei were mediated by their corresponding atrophy patterns. The SN-VTA pattern was associated with less amyloid PET-related memory decline. Together, these findings establish LC and SN-VTA MRI contrast as markers of early neurodegeneration that forecast cognitive decline years before clinical onset.

RevDate: 2026-11-20
CmpDate: 2026-11-20

Laugi H, Hosseinzadehketilateh M, Lee S, et al (2026)

Interpretable Machine Learning Links Group-Specific Plasma Proteomics to Regional Structural Neuroimaging in Alzheimer's Disease.

bioRxiv : the preprint server for biology pii:2026.11.02.763368.

BACKGROUND: Alzheimer's disease (AD) pathology begins years before clinical symptoms, highlighting the need for scalable biomarkers that capture biological changes across the AD continuum. Broader plasma proteomics may capture systemic processes that vary with disease stage, yet their relationship to AD-related brain neurodegeneration remains unclear. We aimed to identify plasma proteomic signatures across cognitively normal (CN), mild cognitive impairment (MCI), and AD and evaluate their neuroanatomical associations.

METHODS: We analyzed 146 plasma analytes from 565 Alzheimer's Disease Neuroimaging Initiative (ADNI) participants (58 CN, 396 MCI, 111 AD). Group-specific proteomic signatures were identified using pairwise classification models with nested 5×5 cross-validation. SHAP quantified feature importance, with the top 15 proteins per comparison being prioritized for MRI association analysis. We analyzed 103 regional structural MRI volumes harmonized across 57 acquisition sites using ComBat. Separate ordinary least squares regression tested protein-MRI associations, adjusting for age, sex, APOE ε4, diagnosis, and intracranial volume, followed by Benjamini-Hochberg false discovery rate (FDR) correction.

RESULTS: Classification models using proteomic data achieved AUC of 0.956 ± 0.017 for CN vs MCI, 0.963 ± 0.011 for MCI vs. AD, and 0.836 ± 0.085 for CN vs. AD. SHAP identified group-dependent proteomic signatures. No protein-MRI associations survived FDR correction for CN vs. MCI. In MCI vs. AD, higher cortisol was associated with lower left precuneus and superior parietal volumes, while higher osteopontin was associated with lower left paracentral and accumbens volumes. In CN vs. AD, higher vitronectin was associated with lower posterior corpus callosum volume.

CONCLUSION: These findings suggest that plasma proteomics capture group-specific systemic biological signals across the AD continuum. Linking ML-prioritized plasma proteins to regional brain structure provides neuroanatomical context for blood-based biomarker discovery.

RevDate: 2026-11-20
CmpDate: 2026-11-20

Riley E, Mabry SA, MacMillan MK, et al (2026)

ADRA2B genetic polymorphism modulates vagus nerve stimulation response.

bioRxiv : the preprint server for biology pii:2026.11.03.763718.

INTRODUCTION: Given interest in vagus nerve stimulation (VNS) as a potential therapy for Alzheimer's disease, due to its hypothesized influence on the noradrenergic (NA) system, there is a need to understand the pronounced individual differences in responsiveness to VNS in aging. We tested whether a genetic polymorphism related to NA signaling, the Δ301-303 deletion in the ADRA2B receptor, modulates transcutaneous auricular (taVNS) effects on task-related pupillary responses or pupil-linked cortical activity in noradrenergic projection territory.

METHODS: Forty-one adults (61% deletion carriers; ages 19-79) performed a visual oddball task during a sham-controlled single-blind crossover taVNS trial. Of these people, 25 (68% deletion carriers) also performed the same task with simultaneous fMRI.

RESULTS: ADRA2B genotype predicted the taVNS effect on oddball pupillary responses (t(37) = 3.03, p = .004, d = 0.84). Deletion carrier responses were more likely to increase, while non-carrier responses decreased. Carriers showed stronger spatial alignment between pupil-BOLD coupling and cortical norepinephrine transporter (NET) expression (t(22) = 2.82, p = .010, adjusted d = 1.21). This difference was selective to NET among 19 PET maps (all other p > .11). The individual effect of taVNS predicted NET alignment of pupil-BOLD coupling (ρ = .45, p = .023).

CONCLUSIONS: ADRA2B Δ301-303 deletion status, which is thought to increase NA availability, predicts the direction of the pupillary response to taVNS and how tightly pupil-linked BOLD activity aligns with cortical noradrenergic projection territory.

RevDate: 2026-11-20
CmpDate: 2026-11-20

Li H, Gross ER, Devine A, et al (2026)

Subcellular Spatial Profiling Unveils Links Between Neuritic Plaques with Selective Tau Vulnerability in Alzheimer's Disease.

bioRxiv : the preprint server for biology pii:2026.11.05.764692.

Alzheimer's disease (AD) features widespread extracellular amyloid-β plaques but selective intraneuronal tau accumulation in cortical layers II/III and V, while layer IV remains relatively resistant. Here, we combined subcellular spatial transcriptomics with co-registered Aβ and pTau immunohistochemistry to determine why neurons exposed to comparable plaque-associated pathology differ in somatic pTau accumulation. Plaque-associated neuritic stress occurred similarly across layers, but layer IV neurons showed attenuated pTau accumulation and reduced somatic expression of a shared neurite-soma stress program involving DCTN1 , CALM3 , NORAD , and PIN1 . Trajectory analysis within layers identified tau-vulnerable and resistant neuronal states implicating calcium signaling, retrograde transport, and lysosomal function. Notably, astrocytic APOE -neuronal LRP1 co-expression increased significantly along the pTau-vulnerable trajectory, and APOE ε4 was associated with stronger coupling of local plaque pathology to pTau-associated molecular programs. These findings reveal neuronal programs and neuron-glia interactions underlying selective tau vulnerability and resistance in AD, highlighting potential tau-targeting therapeutics.

RevDate: 2026-11-20
CmpDate: 2026-11-20

Mandal P, P Baloni (2026)

Brain proteinopathies associated physiological changes leading to cognitive resilience in Alzheimer's disease.

bioRxiv : the preprint server for biology pii:2026.11.09.765496.

UNLABELLED: Alzheimer's disease (AD) pathology has been well characterized, however the molecular mechanisms underlying resilience to the disease remain understudied. With the growing evidence of individuals who are resilient to AD and generation of cross-cohort multiomics data, it has become feasible to understand these mechanisms. In this study, we integrated longitudinal cognitive assessments, regional neuropathology, and matched prefrontal proteomic and metabolomic profiles across donors from two independent cohorts. We identified that asymptomatic AD (AsymAD) brains exhibited amyloid burdens comparable to AD but had fewer compact plaques, lower regional tau burden, and more restricted TDP-43 pathology. Across matched stages of amyloid, tau, and TDP-43 pathology, AsymAD was consistently distinguished from AD by preservation of mitochondrial translation and bioenergetics, synaptic programs, glutamatergic metabolites, and polyunsaturated membrane lipids. Longitudinal cognitive assessments further separated resilient from vulnerable AsymAD individuals despite comparable amyloid and TDP-43 burden, with vulnerability associated with greater neurofibrillary tangle accumulation. Both AsymAD groups retained a prefrontal proteome close to that of cognitively normal individuals, apart from amyloid-associated proteins, whereas mitochondrial, synaptic, and immune changes were largely confined to AD.

HIGHLIGHTS: AsymAD carries AD-level amyloid with lesser compact plaques, tau, and TDP-43The mitochondrial, lipid, synaptic functions separate AsymAD from AD at every pathology stageResilient and vulnerable AsymAD differ in tangles, not amyloid or TDP-43AsymAD keeps a control-like prefrontal proteome.

RevDate: 2026-11-20
CmpDate: 2026-11-20

Sgourdou P, Vrettos N, Hoxha K, et al (2026)

SilencioM: silencing connected interfering oligonucleotides against MAPT as a potential disease modifying therapeutic for tauopathies.

bioRxiv : the preprint server for biology pii:2026.11.09.765484.

Tauopathies are a diverse group of neurodegenerative diseases whose pathogenesis involves brain accumulation of misfolded, pathological tau (Microtubule Associated Protein Tau -MAPT-). More than twenty tauopathies have been identified thus far that collectively impact millions of people worldwide, of which the most common is Alzheimer's disease (AD). Despite substantial efforts to develop drugs for tauopathies, no effective treatments currently exist, highlighting the urgent need for therapeutics to combat these prevalent and ruinous neurodegenerative diseases. Strategies that target tau are likely to have the greatest impact since tau is the proximal cause of their pathogenesis. Small interfering RNAs (siRNAs) have emerged as a powerful class of precision therapeutics that silence disease-causing genes through RNA interference with favorable safety profiles. Delivery challenges are rapidly being addressed, and siRNA-based approaches are poised to transform the therapeutic landscape of neurological diseases. In this study, we describe SilencioM (Silen cing c onnected interfering o ligonucleotides against M APT) and show its efficacy in markedly reducing tau pathology after a single intracerebroventricular injection in PS19 mice, a mouse model of severe tauopathy. SilencioM targets human, primate, rat and mouse ortholog genes; thus, the same compound can proceed from efficacy studies to Investigational New Drug Application (IND)-enabling studies. SilencioM is simple to manufacture and is administered without encapsulation in lipid nanoparticles and without requirements for lipophilic conjugation, making it a promising candidate for further development as a novel therapeutic for tauopathies, including AD.

RevDate: 2026-11-20
CmpDate: 2026-11-20

Lyu C, Tayran H, Bhattarai P, et al (2026)

Chronic FMNL2 overexpression is associated with changes in brain histology and exploratory behavior in adult zebrafish.

bioRxiv : the preprint server for biology pii:2026.11.09.765478.

Formin-like protein 2 (FMNL2) has been associated with Alzheimer's disease and cerebrovascular pathology and regulates gliovascular remodeling following amyloid exposure. However, the consequences of sustained FMNL2 elevation remain unclear. We generated a transgenic zebrafish line expressing human FMNL2 under the her4.1 promoter and examined adult brain histology and behavior under baseline conditions and following acute amyloid-β42 (Aβ42) exposure. Histological analyses assessed FMNL2 immunoreactivity, overlap between the glial marker BLBP and endothelial tight-junction marker ZO1, synaptic vesicle protein SV2 labeling, and microglial counts. Exploratory behavior was evaluated using the novel tank test and free-movement pattern Y-maze. Compared with uninjected wild-type controls, uninjected FMNL2-overexpressing fish showed higher FMNL2 immunoreactivity, lower BLBP-ZO1 overlap, fewer normalized SV2 puncta, and higher counts of total and morphologically activated microglia. Acute Aβ42 exposure in wild-type animals produced changes in the same direction across these histological endpoints. No significant additional histological changes were detected following Aβ42 exposure in the overexpression background. In the novel tank test, uninjected FMNL2-overexpressing fish had a higher composite boldness index than uninjected wild-type controls. These findings indicate that sustained FMNL2 overexpression is associated with histological changes resembling several responses to acute Aβ42 exposure, together with altered exploratory behavior. They support further investigation of persistent FMNL2 elevation as a contributor to altered glial-vascular organization and cellular responses relevant to Alzheimer's disease.

RevDate: 2026-11-20
CmpDate: 2026-11-20

He Z, Park J, Tan J, et al (2026)

Disease aging clocks in the plasma proteome stratify risk and track preclinical progression.

Research square pii:rs.3.rs-10675323.

Aging is the strongest risk factor for most chronic diseases, yet people of the same chronological age differ in how far disease processes have advanced. Existing plasma proteomic clocks estimate chronological age, or the age of a single organ, but none targets the pathway from aging to a specific disease. Here we developed disease aging clocks by deriving the plasma proteomic composite that maximizes the age-mediated component of disease risk and applied the framework to 31 age-related diseases in 44,526 UK Biobank participants. The resulting disease age gap separated 10-year incidence up to 20-fold among individuals of the same chronological age, and each additional year of gap raised the hazard of type 2 diabetes by 24%, chronic kidney disease by 21% and Alzheimer's disease (AD) by 17%. Among participants who went on to develop disease, the gap was larger closer to diagnosis in 19 of 20 diseases, indicating that it reports preclinical stage rather than fixed susceptibility. Across these 20 diseases, 56% of the gap was orthogonal to chronological and organ-specific clocks. Applied without refitting to Stanford Alzheimer's Disease Research Center participants (n=501), the AD clock was elevated in AD and Lewy body disease but not Parkinson's disease, and tracked plasma biomarkers, cognition and neuroimaging features. Disease aging clocks provide a blood-based measure of the stage of a specific aging-to-disease process years before diagnosis, with potential applications in prevention-trial enrichment and longitudinal disease monitoring.

RevDate: 2026-11-20
CmpDate: 2026-11-20

Lee YR, Raj A, Lopez OL, et al (2026)

Delayed-centrifugation blood collection tube for remote blood biomarker assessment.

medRxiv : the preprint server for health sciences pii:2026.10.30.26366958.

INTRODUCTION: Plasma phosphorylated tau 217 (p-tau217) and amyloid-β 42 (Aβ42) are advancing toward clinical use for Alzheimer's disease (AD), but their reliability can be impacted by preanalytical handling. Although alternative collection tubes with distinct stabilization strategies-P100 (protease inhibitor) and HEMAcollect (hemolysis/platelet-activation minimization)-have been developed to stabilize plasma proteins, how well they preserve these markers remains unresolved; we therefore compared both against fresh standard EDTA tubes.

METHODS: In 40 participants, plasma p-tau217 and Aβ42 were measured (Lumipulse) in paired fresh EDTA, P100, and HEMAcollect samples after 5-day ambient storage. We assessed concentration change, rank-order preservation (Spearman ρ), percentage difference, and diagnostic classification under the p-tau217/Aβ42 ratio and p-tau217 alone.

RESULTS: P100 preserved p-tau217 favorably, with high rank-order correlation (ρ=0.98) and a modest median change (+12.1%), and its classification agreement with fresh EDTA reached 97.5% using p-tau217 alone. HEMAcollect showed greater p-tau217 signal loss (-57.5%). Aβ42 was reduced in both tubes (-72.8% P100; -95.5% HEMAcollect) with loss of rank order, so neither preserved the p-tau217/Aβ42 ratio.

DISCUSSION: Stability was tube- and analyte-specific, and P100 consistently outperformed HEMAcollect-preserving p-tau217 rank order while HEMAcollect reduced signal across analytes. Although neither tube preserved the Aβ42-dependent ratio, P100 shows potential for p-tau217-based workflows. Preanalytical stability must be established analyte by analyte before alternative tubes enter clinical AD diagnosis.

RevDate: 2026-11-20
CmpDate: 2026-11-20

McQuaid GA, Tao S, Shea LL, et al (2026)

Anticholinergic Medications and Health in Adults with Autism or Intellectual Disability.

medRxiv : the preprint server for health sciences pii:2026.10.26.26366518.

OBJECTIVE: Contributors to autistic adults' elevated risk for negative aging-related outcomes, including Alzheimer's disease and related dementias (ADRD), falls, and mortality remain underexplored. One candidate factor is exposure to medications with anticholinergic (AC) effects. Thus, this study assessed prevalence of medications with AC effects, and their associations with ADRD, falls, and mortality across four groups: autism-only, autism+intellectual disability (ID), ID-only, and controls.

METHODS: We conducted a retrospective cohort study of 2017-2019 US linked Medicare and Medicaid claims data for 40+ year-olds. Autism, ID, ADRD, and falls were identified using validated algorithms, and mortality was based on Medicare/Medicaid death indicators. Medications were coded using a comprehensive AC potency scale. AC medication exposure effects and interactions between AC potency and group were examined using modified Poisson regressions. Sensitivity analyses to address indication bias excluded persons prescribed antidepressant and/or antipsychotic medication(s).

RESULTS: All three clinical groups experienced significantly greater AC medication exposure (autism+ID: 92.5%>ID-only: 88.6%>autism-only: 80.0%) than non-autistic/non-ID controls (61.3%). Additionally, AC medications were more frequently associated with ADRD, falls, and mortality in all of these groups. Stepwise associations between AC potency levels and ADRD, falls, and mortality were found, and these effects were more prominent for persons with autism and/or ID relative to the control sample.

INTERPRETATION: This study provides a foundational examination of exposure to AC medication effects and their associations with aging-related outcomes in middle-age and older autistic adults and adults with ID. AC medication exposure represents one potential modifiable risk factor for negative aging-related outcomes in these groups.

RevDate: 2026-11-20
CmpDate: 2026-11-20

Tan EP, Ambaye L, Mahul-Mellier AL, et al (2026)

Autophagy activator AA-20 engages CDK5 to promote lipophagy and improve neurodegeneration-associated phenotypes.

bioRxiv : the preprint server for biology pii:2026.10.30.760220.

UNLABELLED: Lipophagy, the selective degradation of lipid droplets (LDs) by autophagy, has the potential to ameliorate neurodegenerative diseases such as Parkinson's (PD) and Alzheimer's (AD), wherein LD accumulation has been linked to the exacerbation of the proteinopathy component of neurodegeneration. Pharmacological lipophagy inducers remain scarce. We previously identified AA-20 as a novel autophagy activator that acts independently of mTORC1 inhibition, thereby providing a means of stimulating autophagy while avoiding the immunosuppressive side effects associated with direct mTORC1 inhibition. Prior work also showed that AA-20 treatment reduces PolyQ aggregate levels in several C. elegans tissues. Here, we demonstrate that AA-20 enhances LD recruitment to autophagosomes and promotes LD degradation via lysosomal acid lipase activation in murine hippocampal neuronal cells, consistent with lipophagy activation. In human Swedish Amyloid Precursor Protein mutated cerebral organoids, two weeks of AA-20 treatment normalized aberrant lipidomic profiles by selectively reducing various disease-associated lipids, while also correcting the AD-associated electrical hyperexcitability phenotype. Moreover, we identified cyclin-dependent kinase 5 (CDK5), a neuronal kinase linked to AD hyperexcitability and PD pathology, as a target of AA-20. AA-20-induced autophagy and lipid clearance in HT22 cells require CDK5. In a neuronal seeding model of α-synuclein pathology, AA-20 reduced pS129-α-synuclein levels. Collectively, these findings indicate AA-20 can promote lipophagic clearance of LDs and mitigate multiple cellular phenotypes associated with lipidopathy and proteinopathy in neurodegenerative disease models.

SIGNIFICANCE: Neurodegenerative diseases such as Alzheimer's and Parkinson's are associated with impaired autophagy and abnormal lipid droplet (LD) accumulation. Few small molecules enhance neuronal lipid clearance without inhibiting mTORC1, but chronic blockade of which is associated with immunosuppressive and metabolic side effects. This study shows that AA-20, an mTORC1-independent autophagy activator, promotes lipophagic LD clearance in neuronal cells and reduces selected disease-associated lipids in human Alzheimer's cerebral organoids in a lysosomal acid lipase-dependent manner. AA-20 binds CDK5 and appears to modulate, rather than classically inhibit, this neuron-enriched kinase. In an exploratory Parkinson's neuron model, AA-20 also reduced pathological α-synuclein phosphorylation. These findings support further investigation of AA-20 as a tool to probe neuronal lipid clearance and neurodegeneration-associated phenotypes.

RevDate: 2026-11-20
CmpDate: 2026-11-20

Pedersen TJ, Yu J, Li A, et al (2026)

Suvorexant Inversely Affects Phosphorylated Tau in Human Cerebrospinal Fluid and Plasma.

medRxiv : the preprint server for health sciences pii:2026.11.03.26367196.

Alzheimer disease (AD) is characterized by amyloid-β plaques and neurofibrillary tangles of tau. Suvorexant, a dual orexin receptor antagonist, was previously shown to acutely reduce the ratio of phosphorylated tau-181 to unphosphorylated tau-181 (pT181/T181) in cerebrospinal fluid (CSF). However, its effects on plasma pT181/T181 and broader proteomic networks remain unknown. Here, we conducted a secondary analysis of samples from a randomized, placebo-controlled trial of 25 participants receiving placebo or suvorexant 20 mg. Paired CSF and plasma samples were collected longitudinally via indwelling intrathecal and intravenous catheters. Plasma AD biomarkers were quantified by mass spectrometry, and proteomic profiling was performed using the SomaScan 11K assay on samples from hours 0, 16, and 24. Suvorexant increased pT181/T181 in plasma while decreasing it in CSF between 08:00-16:00. At the pathway level, suvorexant increased the extracellular abundance of proteins associated with translation, RNA binding, cytoskeletal organization and endosomal sorting, centrally at 16 hours and peripherally at 24 hours, and decreased cytokine and receptor-ligand signaling and serine protease activity in plasma at 24 hours. As plasma biomarkers are increasingly used for clinical screening and trial enrollment, factors that influence their levels, including medications, must be identified and their effects on interpretation understood.

RevDate: 2026-11-20
CmpDate: 2026-11-20

Ray N, Yang D, Yang Y, et al (2026)

Shared genetic architecture between Alzheimer's disease and blood pressure implicates ACE and NBEAL1 in individuals of European ancestry.

Research square pii:rs.3.rs-11269850.

Background Vascular dysfunction is increasingly recognized as a contributor to Alzheimer's disease (AD), yet the genetic mechanisms linking blood pressure (BP) and AD remain incompletely understood. We investigated shared genetic architecture between AD and systolic blood pressure (SBP), diastolic blood pressure (DBP), and pulse pressure (PP) to identify locus-specific mechanisms connecting vascular regulation and neurodegeneration. Results We analyzed genome-wide association study summary statistics from individuals of European ancestry using global and local genetic correlation and conjunctional false discovery rate (conjFDR), followed by cis-Mendelian randomization (cis-MR), functional annotation, expression quantitative trait locus associations, and AD-specific multi-omic evidence. AD showed modest negative global genetic correlations with BP but significant local genetic correlation at eight regions. ConjFDR identified 42 high-confidence variants across 22 independent LD regions, with PRKD3 , NBEAL1 , NDUFAF6 , SPI1 , and the APOE region supported by both local genetic correlation and conjFDR. Cis-MR provided evidence for effects of BP on AD at multiple regions, with ACE and the APOE region showing significant effects for all three BP traits. Integrative analysis most strongly prioritized the APOE region, with convergent evidence at ACE and NBEAL1 and additional signals implicating immune and mitochondrial pathways. Conclusions The genetic relationship between AD and BP is characterized by heterogeneous, locus-specific overlap not fully captured by genome-wide genetic correlation. Convergent evidence implicates APOE , ACE , NBEAL1 , and other loci involved in vascular, immune, and mitochondrial biology, supporting multiple, partially BP-trait-specific mechanisms linking vascular regulation to AD.

RevDate: 2026-11-20
CmpDate: 2026-11-20

Harper-Alexander V, Peterson S, Sadikova S, et al (2026)

Sex-specific gene and isoform expression characterizes hippocampal aging in rhesus macaques.

bioRxiv : the preprint server for biology pii:2026.11.04.764396.

Aging produces widespread transcriptomic alterations that extend beyond changes in gene expression to include changes at the isoform level. Declining splicing fidelity, including increased intron retention and aberrant isoform expression, has been proposed to contribute to cellular dysfunction; however, the extent and biological significance of isoform-specific changes in the aging brain remain poorly understood. Age-related cognitive decline has also been associated with neuroinflammation and the development of a chronic inflammatory state, or "inflammaging," within the brain. Here, we used short- and long-read RNA sequencing to characterize gene- and isoform-level changes associated with hippocampal aging across sex in 24 rhesus macaques. We identified 594 age-associated differential isoform expression events, comprising both shared and sex-specific changes. Inflammatory pathways, including TNF-α-NF-κB signaling, interferon responses, and complement pathways, were enriched across both sexes. Weighted gene co-expression network analysis (WGCNA) further identified sex-specific modules associated with inflammatory, glial, mitochondrial, and hormone-responsive processes. Notably, several age-associated changes were detected at the isoform level despite limited or absent corresponding gene-level differences, highlighting transcript-level regulation as an additional dimension of brain aging that may be overlooked by gene-level analyses. To investigate the relationship between aging and Alzheimer's disease (AD), we independently performed WGCNA on the rhesus macaque cohort and a publicly available human hippocampal AD single-nucleus RNA-sequencing dataset (GSE268609). Cross-species module preservation and gene overlap analyses identified shared genes between age-associated and AD-associated networks, with pathway enrichment implicating glial function, inflammation, and mitochondrial biology. Together, these findings highlight sex-associated differences in hippocampal transcriptomic aging, underscore the importance of isoform-level regulation, and identify shared transcriptional signatures between normal aging and AD-associated pathways.

RevDate: 2026-11-20
CmpDate: 2026-11-20

Li H, Liu Y, Lin C, et al (2026)

TailEnrich enables discovery of dysregulated genes through disease sample enrichment testing.

bioRxiv : the preprint server for biology pii:2026.11.04.764457.

UNLABELLED: Identifying differentially expressed genes is fundamental to elucidating the molecular mecha nisms underlying complex diseases. However, in complex disorders such as Alzheimer's disease (AD), the genes exhibiting dysregulated expression may vary among patient subsets, reflecting the heterogeneity of the underlying pathological processes. Consequently, pathogenic genes are profoundly dysregulated in only a subset of patients. Conventional differential expression tools, such as DESeq2 and edgeR, are primarily designed to detect population-level expression shifts and may have limited power to identify subgroup-specific dysregulation. To overcome this limitation, we developed TailEnrich, a novel com putational method that discovers dysregulated genes within patient subsets. TailEnrich independently tests the extreme left (downregulated) or right (upregulated) tails of a gene's expression distribution for disease sample enrichment. We quantify this enrichment using a new metric, i.e. the PE (Percentage of Enriched disease samples) score. On simulated datasets, TailEnrich demonstrates markedly improved accuracy over DESeq2 and edgeR in identifying dysregulated genes specific to patient subsets. Applied to AD gene expression data, TailEnrich uncovers a distinct, biologically relevant set of genes within key pathological pathways that are missed by mean shift-based approaches. TailEnrich provides a novel method for identifying dysregulated genes, and readily extends to other omics data including genomic variants and proteomics to uncover pathogenic genes in complex diseases.

TailEnrich is implemented in R. The source code and documenta tion are freely available at https://github.com/Sanke926/Tailenrich .

RevDate: 2026-11-20
CmpDate: 2026-11-20

Mukhija M, Chandra A, Devi K, et al (2026)

Identification of novel compounds from Olea Europaea targeting hDus2 as potential anticancer agents: a molecular docking and molecular dynamics study.

Frontiers in oncology, 16:1845700.

INTRODUCTION: Leukemia, a type of blood cancer, ranks among the top causes of cancer-related fatalities. Human tRNA-dihydrouridine synthase 2 (hDus2) catalyzes the conversion of uridine to dihydrouridine in the tRNA and is overexpressed in cancer cells, facilitating the translational process required for cancer cell growth. Inhibition of hDus2 reduces cancer cell growth and viability while increasing apoptosis sensitivity under stress, making it an excellent cancer target. Olea Europaea is known to be abundant in flavonoids, polyphenols, vitamins, and antioxidants, and shows immense potential in providing health benefits. The varied properties of these compounds are very significant in the prevention of disorders such as Alzheimer's and Cancer.

METHODOLOGY: Olea Europaea extract was tested for anti-cancer activity, followed by identification of potential leads using in silico methods. The compounds from the OliveNet database were screened against the hDus2 enzyme. The identified compounds were further validated using Molecular Dynamics (MD) Simulation.

RESULTS: Molecular docking studies with the Glide module revealed that several compounds showed high affinity for hDus2. The top five compounds out of six hundred seventy six compounds were selected for molecular dynamics simulations to study their structural stability and conformational dynamics in the presence of solvent molecules.

CONCLUSION: Binding free energy calculations revealed that all complexes were stable, with P166 and P161 exhibiting the highest binding potential against hDus2. These findings lay the foundation for the development of novel anti-cancer therapeutics targeting leukemia.

RevDate: 2026-11-20
CmpDate: 2026-11-20

Maximov Y, Volkov A, Chattopadhyay T, et al (2026)

Personalized Prediction of Differences in fMRI Connectivity Estimates Across Preprocessing Pipelines.

bioRxiv : the preprint server for biology pii:2026.11.04.763874.

Longitudinal functional MRI of the human brain is valuable for tracking changes in functional connectivity (FC) associated with disease progression or treatment response. Even so, measured FC values depend on preprocessing, and nuisance regression and temporal filtering affect individuals differently. We examined whether we could use earlier scans to predict how preprocessing would affect a later scan. In 69 ADNI (Alzheimer's Disease Neuroimaging Initiative) participants scanned three times, we measured how nuisance regression and filtering, alone and in sequence, changed the measured FC. A ridge regression model combined these responses with baseline FC from the third scan to predict the effect of reversing the processing order. Just four coefficients were shared across 79,800 connections. In leave-one-participant-out testing, mean squared error was 0.012, compared with 0.017 for predicting the same average response for everyone. It outperformed the best of seven alternative predictions chosen for each participant (0.013; normalized gain 0.069, 95% bootstrap interval 0.006-0.134), with lower error in 44 of 69 participants. About half the benefit of using each person's earlier responses, rather than the average across participants, came from which connections changed. This advantage persisted after accounting for acquisition variables. The ADNI-trained model reduced mean error in ten Midnight Scan Club participants without refitting. These results support using personal preprocessing history to predict changes in connectivity estimates on newly acquired scans.

RevDate: 2026-11-20
CmpDate: 2026-11-20

Neel MJ, Vukalovich N, Porahang P, et al (2026)

Midlife nonlinearities across scale in Biondi body amyloid formation in the human choroid plexus.

bioRxiv : the preprint server for biology pii:2026.11.04.764372.

Human choroid plexus epithelial cells (CPECs), which produce cerebrospinal fluid and form the blood-cerebrospinal fluid barrier, accumulate discrete intracellular amyloid inclusions called Biondi bodies (BBs). Using systematic manual and machine learning approaches on the choroid plexus glomus, we determined the percentages of CPECs containing thioflavin S-stained BBs as well as BB load and spatial distributions in whole slide images from 77 cases across the human lifespan. On average, BB prevalence was near zero until age 40, rose steeply in the 5th and 6th decades, and exceeded 50% after age 70. As prevalence plateaued, BB load continued to rise with age. Accelerated BB accumulation was seen in two cases of diabetic ketoacidosis, including a 16-year-old, while an 85-year-old with the relatively rare APOE2/E2 genotype had fewer BBs than expected. BB prevalence in the choroid plexus glomus was not associated with Alzheimer's disease, but was lower in females than males. Notably, spatial clustering of BBs was universal across cases while nearest-neighbor analyses suggested cell-to-cell, prion-like BB spread that can account for the nonlinearities seen at tissue and population scales. The abrupt, nonlinear BB accumulation during midlife coincides with or precedes other common aging-associated neuropathologies of the human brain, consistent with broad BB and ChP contributions to brain aging and disease.

RevDate: 2026-11-20
CmpDate: 2026-11-20

Guo S, Yang X, Dong Y, et al (2026)

Caudate nucleus aging and its association with brain disorders.

bioRxiv : the preprint server for biology pii:2026.10.28.762543.

The caudate nucleus supports cognition and goal-directed behavior, undergoes age-associated changes, and is implicated in substance use, psychiatric, and neurodegenerative disorders. However, how aging alters its diverse cell types and how such changes relate to diseases remains poorly understood. To address these questions, we assembled single nucleus transcriptomic atlases of the caudate tissue, comprising 963,842 nuclei from 178 human donors, including controls and individuals with alcohol use disorder (AUD) or opioid use disorder (OUD), and 83,699 nuclei from six healthy rhesus macaques. We also curated 3,139 bulk RNA-seq profiles from the caudate and other brain regions spanning controls and multiple diagnostic groups, as well as paired RNA and chromatin accessibility profiles from 257,524 caudate nuclei across 161 control and AUD donors. These datasets enabled comparisons across age, species, brain regions, and diagnostic groups. We found shared glial aging features in humans and macaques, whereas neuronal changes were more divergent. Inferred neuron-to-neuron communication declined with age, with greater declines in AUD. Both transcriptional and chromatin accessibility profiles showed nonlinear age-associated patterns, with pronounced changes in later adulthood. In donors with AUD, age-associated changes appeared earlier, with altered trajectories in lipid metabolism, mitochondrial function, and neuronal signaling. Across comparisons involving AUD, OUD, bipolar disorder, schizophrenia, and Alzheimer disease, mitochondrial function and fatty acid metabolism emerged as consensus features linking caudate aging to diseases, although the direction and extent of overlap varied by disorder and brain region. Together, these findings define cellular and regulatory features of primate caudate aging and reveal shared and context-dependent relationships between aging and brain disorders.

RevDate: 2026-11-20
CmpDate: 2026-11-20

Rayaprolu S, Malepati S, Dammer EB, et al (2026)

Network analysis of mouse brain proteomes resolves molecular and cellular endophenotypes of aging and Aβ pathology.

bioRxiv : the preprint server for biology pii:2026.11.05.764669.

Aging and Alzheimer's disease (AD) pathology exert both shared and distinct effects on the brain, yet their relative contributions to molecular alterations remain poorly defined. Here we performed tandem mass tag proteomics across the lifespan in wild-type and 5xFAD mice and integrated these data with human brain proteomic networks to resolve aging- and amyloid-β (Aβ)-associated molecular programs. We quantified 8,535 proteins and identified 51 co-expression modules representing neuronal, mitochondrial, glial, vascular and proteostatic pathways. Aging emerged as the predominant driver of proteomic remodeling, with widespread alterations in RNA metabolism, protein translation, and neuronal pathways occurring independently of Aβ pathology. In contrast, Aβ selectively modified a subset of age-dependent processes, including suppression of mitochondrial ATP biosynthetic machinery and amplification of astrocytic and microglial activation states. These key aging and disease-related molecular signatures were highly conserved in human AD brain proteomes. Together, our findings establish aging as the primary determinant of brain proteome organization while revealing specific mechanisms through which Aβ pathology reshapes age-associated biological processes. Our results also highlight molecular mechanisms of human aging and AD pathology that can be modeled in mouse models.

RevDate: 2026-11-20
CmpDate: 2026-11-20

Morin TM, Chen HY, Aghasoltan S, et al (2026)

Dopamine Synthesis Capacity and Tau Pathology Differentially Modulate Rest-to-Task Functional Network Dynamics.

bioRxiv : the preprint server for biology pii:2026.11.04.764247.

UNLABELLED: Optimal cognition relies on large-scale functional brain networks which balance segregation at rest with selective integration during task performance. In aging, these network dynamics are altered. We examined two prominent features of brain aging: dysregulated dopamine function and Alzheimer's disease (AD)-related pathology to examine impacts on brain network dynamics. Young adults and cognitively unimpaired older adults completed resting-state and task-based fMRI and PET imaging of dopamine synthesis capacity ([ [18] F]fluoro-m-L-tyrosine). Older adults were classified as β-amyloid negative/positive using [ [11] C]Pittsburgh Compound-B PET (PiB-or PiB+) and underwent tau-PET scanning ([ [18] F]flortaucipir). Greater rest-to-task network stability and task-related network segregation were associated with better subsequent memory. Compared to young adults, PiB+ older adults showed reduced network stability and both PiB+ and PiB-older adults showed reduced segregation during rest. Higher ventral striatal dopamine synthesis capacity was associated with greater stability within associative networks in young adults, but this relationship was attenuated in older adults and absent in PiB+ participants. In PiB+ older adults, higher tau burden was associated with a task-induced collapse of network segregation across large-scale networks. These findings reveal dissociable influences of dopamine and tau on rest-to-task network organization, highlighting the value of integrating neuromodulatory and pathological markers in aging research.

AUTHOR SUMMARY: As we age, our brains become less efficient at balancing network segregation at rest with selective integration during task states. In this study, we combine brain imaging methods to examine how dopamine, a key neuromodulator, and tau pathology, a hallmark of Alzheimer's disease, influence large-scale brain network dynamics. We show that dopamine supports stable and well-organized brain networks while tau pathology disrupts this organization during a cognitive task. These opposing influences help explain why some individuals maintain cognitive resilience while others show early network dysfunction, providing new insight into mechanisms of cognitive aging and age-related pathology.

RevDate: 2026-11-20
CmpDate: 2026-11-20

Wen X, Shehreen S, Neumann A, et al (2026)

Broad Cognitive and Motivational Enhancement through M 4 -Selective Muscarinic Modulation.

bioRxiv : the preprint server for biology pii:2026.11.05.764685.

The muscarinic M 4 subtype of acetylcholine receptors is part of agonist compounds considered treatment options for Schizophrenia and Alzheimers disease, but how M 4 -subtype selective modulation affects cognition and motivation is largely unknown due to dose-limiting side effects, a scarcity of receptor-selective compounds, and missing multi-domain assessments of cognition. Here, we surmount these constraints by utilizing a M 4 -selective positive allosteric modulator (PAM) to assess in nonhuman primates a broad array of endpoints spanning motivational effort control and multiple executive function domains. We found broad dose-dependent performance improvements of set shifting indexing cognitive flexibility, visual search indexing selective attention, antisaccade performance indexing inhibitory control, visuospatial maze learning, and temporal order serial object learning, while working memory span was non-systematically modulated. In addition, the M 4 PAM reduced effort avoidance in an effort-based choice task documenting a pro-motivational effect. Task-composite performance scores showed pro-cognitive effects across multiple doses and an effective dose range for individual subjects in the absence of adverse dose-limiting cholinergic side effects. Together, the broad pro-cognitive and pro-motivational multi-task profile of M 4 PAM modulation suggests that the M 4 receptor is a master regulator of executive cognitive functioning, possibly acting on domain-general neural processes across the prefrontal-striatal circuits.

RevDate: 2026-11-20
CmpDate: 2026-11-20

Rocha A, Soares C, Scop Medeiros M, et al (2026)

Tau PET Braak staging across the Alzheimer Disease continuum using Flortaucipir and MK6240.

medRxiv : the preprint server for health sciences pii:2026.11.01.26367034.

Tau positron emission tomography (PET) staging is increasingly used to stratify Alzheimer's disease (AD), yet cross-tracer interchangeability remains unestablished. In a prospective head-to-head study of 682 individuals across the aging-to-AD continuum, we compared tau PET Braak staging derived from [ [18] F]Flortaucipir and [ [18] F]MK6240. While both tracers showed high internal adherence to hierarchical Braak patterns (89-92%), cross-tracer agreement was limited (43%, weighted κ = 0.54) and fell to 14- 23% at early-to-intermediate stages, a key window for therapeutic intervention. Discordance was strongly directional: in over 90% of discordant cases [ [18] F]MK6240 assigned a higher stage, on average approximately one stage above [ [18] F]Flortaucipir. [ [18] F]MK6240 upstaging was associated with greater Aβ burden, adverse plasma biomarker profiles, and worse cognitive performance. Stage-frequency benchmarking against an external neuropathological cohort (N = 4,422) revealed that PET staging lags neuropathology by ∼2 Braak stages for [ [18] F]MK6240 and ∼3 for [ [18] F]Flortaucipir in the early phases of disease, with progressive convergence at later stages. Tau PET Braak staging is internally coherent within tracers but not interchangeable across them, with [ [18] F]MK6240 systematically assigning higher stages than [ [18] F]Flortaucipir. This biologically meaningful discordance, most pronounced at early stages, has direct implications for patient selection and staging for clinical trials and practice, necessitating tracer- aware harmonization strategies.

RevDate: 2026-11-20
CmpDate: 2026-11-20

Cao X, Wang Y, Sun H, et al (2026)

A multi-scale cell-type resolved map of trans -regulatory architecture in the aging human brain.

medRxiv : the preprint server for health sciences pii:2026.11.05.26367384.

Mapping genetic effects on distal genes and regulatory programs is essential for understanding how genetic variation influences complex diseases; yet trans -QTL discovery remains limited by weak effect sizes, extensive multiple testing and poor reproducibility. Here, we introduce TransMap , a generalizable computational framework that combines multi-scale trans -QTL mapping with multi-phenotype genetic colocalization to improve the discovery and interpretation of distal regulatory variants. Beyond individual trans -eGenes, TransMap constructs local co-regulatory program phenotypes that account for background expression variation to improve the detection of weak, coordinated distal genetic effects. Across a broad range of simulation settings, TransMap achieved 9.2-36.7% higher trans -QTL discovery power than existing methods while maintaining well-controlled type I error rates. We applied TransMap to bulk and single-nucleus transcriptomic profiles from the aging human brain in the ADSP Functional Genomics Consortium (FunGen-AD), further integrating proteomic, glycoproteomic and metabolomic biomarker measurements (average N= 476 donors). Genome-wide fine-mapping of TransMap single-gene and program-level QTL yielded variant annotations with 2.75-2.88x heritability enrichment across 57 complex diseases and traits (average N= 307K), with complementary heritability information captured across regulatory scales. Multi-phenotype colocalization identified 49,532 trans -regulatory events supported by shared genetic signals with cis -eQTL or biomarker-QTL, including 1,825 candidate cis-trans-biomarker regulatory configurations. TransMap further revealed an asymmetric cross-cell-type regulatory architecture in which neuronal cis -regulatory signals preferentially associate with coordinated glial trans -regulatory responses, supported by co-culture experiments and spatial transcriptomics. Alzheimer's disease (AD) GWAS-prioritized colocalization identified trans -regulatory associations in 115 AD-associated loci, including a KNOP1 cis -eQTL associated in trans with a microglial regulatory program containing MS4A4E , with additional support from statistical mediation analysis. TransMap provides a multi-scale, cell-type-resolved atlas of trans -regulatory variation and a generalizable framework for elucidating the regulatory architecture of complex diseases.

RevDate: 2026-11-20
CmpDate: 2026-11-20

Kubit BM, Asthagiri A, Lopez KL, et al (2026)

Music-Synchronized Gamma Light Stimulation Strengthens Theta-Gamma Coupling in Older Adults with Cognitive Impairment: Results from a Randomized Feasibility Trial.

medRxiv : the preprint server for health sciences pii:2026.11.06.26367319.

Noninvasive clinical innovations for restoring gamma activity via sound and light stimulation have the potential to improve memory and cognitive abilities in Alzheimer's disease. We assessed whether pairing music with theta- and gamma-band light changes memory-supporting neural dynamics, and whether those changes track cognition. In an ongoing randomized feasibility trial, 38 older adults with cognitive impairment completed eight weeks of an audiovisual intervention. The treatment group (n = 19) listened to self-selected music while viewing light stimulation that consisted of a 39-Hz gamma-band signal modulated by delta- and theta-band musical rhythms. The control group (n = 19) listened to podcasts while viewing synchronized lights without the gamma frequency (delta-band only). Before and after the 8-week intervention, participants completed a face-name association task and the Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog). Individuals in the treatment group showed significant improvements on a face-name association task and the ADAS-Cog. Cluster-based permutation testing showed a larger increase in phase-amplitude coupling between acoustic theta phase and frontal EEG gamma amplitude in the treatment group compared to the control group. Across participants, increases in stimulus-driven theta to EEG-gamma phase-amplitude coupling were associated with improvements in memory. These preliminary results suggest that theta-gamma stimulation delivered through music and lights strengthens cross-frequency coupling, and may correspondingly strengthen associative memory.

RevDate: 2026-11-20
CmpDate: 2026-11-20

Enbar-Salo N, Palmer P, Munro C, et al (2026)

Memory Self-Awareness Phenotypes are Associated with Alzheimer's Disease Biomarker Burden and Clinical Progression in Amnestic Mild Cognitive Impairment.

medRxiv : the preprint server for health sciences pii:2026.11.03.26367187.

BACKGROUND: Altered memory self-awareness is common in mild cognitive impairment (MCI), but its relationship to Alzheimer's disease (AD) pathology and progression remains unclear.

METHODS: Using 590 amnestic MCI ADNI participants, memory self-awareness was derived from participant-informant discrepancies on the memory subdomain of the Everyday Cognition questionnaire. Heightened awareness and unawareness subscores were calculated, and k-means clustering identified four phenotypes. Associations with cerebrospinal fluid (CSF) and positron emission tomography (PET) were examined, and clinical progression was assessed using Cox models.

RESULTS: Aware and Unaware groups showed lower CSF amyloid-β, and higher CSF phosphorylated tau and PET amyloid. The Unaware phenotype was associated with increased progression risk (hazard ratio 2.41, 95% CI 1.48-3.92), whereas the Worried Well phenotype showed reduced risk (hazard ratio 0.58, 95% CI 0.34-0.99).

CONCLUSIONS: Multidimensional assessment of memory self-awareness identifies biologically and prognostically distinct subgroups within MCI and may improve risk stratification in prodromal AD.

RevDate: 2026-11-20
CmpDate: 2026-11-20

Dai Y, Wood CS, Jiang X, et al (2026)

PRISM-AD quantifies clinical and genetic contributions to cognitive risk prediction.

medRxiv : the preprint server for health sciences pii:2026.11.03.26367206.

BACKGROUND: Older adults with high inherited Alzheimer's disease (AD) susceptibility can still be cognitively normal (CN). An overall risk estimate alone does not show the cognitive and genetic contributions within a forecast.

OBJECTIVE: To quantify clinical and genetic contributions to cognitive prognosis.

METHODS: PRISM-AD combined nonlinear clinical functions and a polygenic risk score (PRS) term in 4,435 European-ancestry participants. Participant-level internal validation evaluated first recorded mild cognitive impairment (MCI) after CN in 908 participants and AD dementia after MCI in 714, within three or five years. Separately fitted comparators used identical inputs. Post hoc clinical-course comparisons used regression with robust standard errors and Benjamini-Hochberg (BH) correction.

RESULTS: PRISM-AD using current assessments achieved average precision of 0.2996 and 0.4094 for three- and five-year CN-to-MCI, with estimates close to logistic regression. No PRISM-AD PRS increment met BH q < 0.05. Three-year first-MCI forecasts characterized risk contributions in 893 initially CN participants. A retrospective comparison over available follow-up included 95 participants with later AD and 701 with CN at their last diagnostic assessment. Modeled genetic factors were higher in later AD in nine of ten shared cognitive-risk deciles. After adjustment for modeled cognitive risk and fold, the genetic-factor ratio was 1.135 (nominal 95% CI, 1.073 to 1.201, BH q < 0.001).

CONCLUSIONS: Higher genetic contributions were associated with later AD at comparable modeled cognitive risk. These exploratory profiles require independent validation before use in cognitive follow-up or prevention research.

RevDate: 2026-11-20
CmpDate: 2026-11-20

Niu X, Sun Q, Wisch JK, et al (2026)

Stage-Specific Roles of Plasma GFAP in Linking Amyloid Cascade in Alzheimer Disease.

medRxiv : the preprint server for health sciences pii:2026.11.03.26366374.

INTRODUCTION: Astrocytic reactivity, measured by plasma glial fibrillary acidic protein (GFAP), is robustly elevated across the Alzheimer disease (AD) continuum, yet its relationship with the amyloid cascade remains poorly understood.

METHODS: We integrated plasma GFAP with multimodal AD biomarkers including cerebrospinal fluid (CSF) or plasma Aβ (Aβ42/40), Aβ and tau positron emission tomography (PET), structural MRI, and clinical severity, across a discovery cohort (Knight Alzheimer Disease Research Center, n=278) and an independent replication cohort (Alzheimer's Disease Neuroimaging Initiative, n=236).

RESULTS: In both cohorts, plasma GFAP mediated the association of soluble Aβ42/40 (CSF in the Knight ADRC; plasma in ADNI) with Aβ PET, as well as the association of Aβ PET with tau PET in the overall samples, which remained significant after false discovery rate (FDR) correction. Among tau-negative individuals, GFAP mediated the association between CSF Aβ42/40 and Aβ PET in Knight ADRC, but this effect did not survive FDR correction with plasma Aβ42/40 in ADNI. In Aβ-positive individuals, GFAP mediated the association between Aβ PET and tau PET burden in both cohorts, but survived correction only in ADNI. Interaction findings were partially replicated across cohorts. Exploratory plasma proteomics further revealed a GFAP-associated protein network enriched for extracellular matrix (ECM)-immune remodeling network.

DISCUSSION: These findings reveal stage-specific associations of plasma GFAP with the amyloid cascade and implicate an astrocyte-centered ECM-inflammatory axis, which may inform future diagnostic panels or targeted therapies.

CLINICAL TRIAL REGISTRATION: Alzheimer's Disease Neuroimaging Initiative 3, ClinicalTrials.gov, NCT02854033 .

RevDate: 2026-11-20
CmpDate: 2026-11-20

Gi Y, Lim H, Park S, et al (2026)

Anatomical Interfaces as a Complementary Substrate for Structural MRI Representation in Alzheimer's Disease.

Research square pii:rs.3.rs-11067124.

Background Structural MRI analysis of Alzheimer's disease (AD) commonly relies on region-of-interest (ROI) summaries or voxel-level deep networks, neither of which explicitly quantifies the physical interfaces shared by adjacent brain regions. We investigated whether these anatomical interfaces provide structural information complementary to conventional regional measures. Methods T1-weighted MRI was segmented into 79 anatomical regions using a pretrained nnU-Net. Each region was represented as a graph node with six morpho-textural descriptors, while edges were defined only between regions sharing voxel-level face contact and characterized by Structural Contact and Boundary Appearance features. Results Correlation analyses showed generally limited redundancy between node- and interface-level descriptors, supporting partially distinct representational information. Node-controlled analyses further showed that selected interface features remained significantly associated with disease stage after adjustment for the morpho-textural characteristics of both connected regions, indicating that interface-level variation was not fully reducible to regional abnormalities. White matter hypointensity interfaces repeatedly emerged among the retained stage-associated effects. Selected Structural Contact features also showed convergent associations with clinical severity across CDR-SB, ADAS-Cog13, and MMSE. Representation ablation demonstrated that disrupting anatomical adjacency or removing interface attributes reduced classification performance, supporting the contribution of anatomically organized relational information. The full representation also improved multi-class classification relative to conventional ROI-vector and voxel-level baselines, with this advantage preserved on the independent NACC cohort without fine-tuning. Conclusions These findings indicate that anatomical interfaces provide measurable and complementary structural information beyond conventional region-wise morphometry, offering an interpretable framework for representing inter-regional structural relationships in neurodegenerative disease.

RevDate: 2026-11-20
CmpDate: 2026-11-20

Potthoff RD, Steffen S, van Rentergem JA, et al (2026)

Interpreting Functional Connectivity in Alzheimer's Disease as Cognitive Processes: Multinomial Processing Trees and the Common Model of Cognition.

Research square pii:rs.3.rs-10981827.

Cognitive process models and brain connectivity analyses both provide a higher resolution into what cognitive functions are engaged during cognitive tasks than traditional methods. However, the two methods are typically applied in isolation. Our goal is to combine them, and ask which impaired cognitive functions are associated with a specific connectivity signature. Participants were 1,127 participants from the Alzheimer's Disease Neuroimaging Initiative (ADNI), of varying cognitive status at their last included time point: Cognitively Normal = 554, Mild Cognitive Impairment = 386, Alzheimer's Disease = 187. We combine Bayesian multinomial processing tree (MPT) cognitive modelling with resting-state functional connectivity analysis guided by the Common Model of Cognition. MPT modelling showed that Learned and Delayed Retrieval processes had the largest diagnostic differences (η[2] ≈ 0.40), while Short-term Retrieval was unaffected. MPT parameters were correlated with widespread brain connectivity changes. However, brain connectivity changes were collinear, and mostly attributable to the diagnostic group. The exception was the Delayed Retrieval process parameter, which was associated with functional connectivity between areas associated with Working Memory and areas associated with Long-Term Memory, even when corrected for all other parameters. Combining the two analyses allowed us to link a function defined at the neural level to a function defined at the behavioral level. This article describes the potential and current limits of joining the two classes of models.

RevDate: 2026-11-20
CmpDate: 2026-11-20

Fatima F, Sajid MI, Shirazi AN, et al (2026)

Blood-brain barrier-penetrant pharmacological strategies for neuroinflammation in Alzheimer's disease: small molecules and engineered peptides.

Frontiers in pharmacology, 17:1983306.

Recognition of Alzheimer's disease (AD) as a neuroinflammatory disorder, alongside amyloid-β and tau pathology, necessitates the development of innovative therapies capable of overcoming blood-brain barrier (BBB)-mediated limitations to brain drug delivery. This review discusses current efforts to develop BBB-permeable small molecules and peptide-based therapies targeting the neuroimmune modulators TREM2, the NLRP3 inflammasome, RIPK1, and the cGAS-STING signaling pathway, with consideration of the concept of the neurovascular paradox. Despite promising recent developments, the trade-off between permeability, selectivity, and cytotoxicity remains a significant issue. The current findings indicate that BBB penetration, the timing of microglial targeting, immunosuppressive effects, and neuroimmune homeostasis should be considered when seeking to modulate neuroinflammation effectively. Novel delivery systems, such as those using cell-penetrating peptide shuttles and antibody-based transport systems, may help address BBB limitations, and biomarker-guided treatment is increasingly important. Overall, this review reframes brain drug delivery not only as a function of pharmacokinetic parameters but also as part of a system integrating neurovascular physiology, neuroimmunology, and medicinal chemistry.

RevDate: 2026-11-20
CmpDate: 2026-11-20

Santana C, Lebel C, Frayne R, et al (2026)

Midsagittal Corpus Callosum Parameterization: A Framework for Spatially Detailed Diffusion MR Imaging Analysis.

ArXiv pii:2611.19066.

The corpus callosum (CC) is the largest white matter structure in the human brain and plays a central role in interhemispheric communication. Diffusion MR imaging is widely used to investigate microstructural organization, but commonly used analysis approaches have important limitations. Voxel-based methods rely heavily on accurate inter-subject registration and smoothing choices, tract-based spatial statistics (TBSS) restricts the analysis to a narrow white matter skeleton, and parcellation approaches reduce spatial detail by averaging diffusion measures over relatively large regions. In this work, we introduce a parameterization framework for the analysis of the midsagittal CC that resamples the structure using a standardized grid of points, establishing a geometric correspondence across individuals without explicit inter-subject registration. In a test-retest dataset, the method provided stable measurements while covering most of the midsagittal CC, and sensitivity analyses showed that results in the central CC changed little under perturbations of the input CC mask, whereas peripheral regions were more sensitive. The framework was further evaluated in group analyses of aging and Alzheimer's disease in datasets that differ in acquisition protocol and spatial resolution. Effect-size maps and quantitative comparisons showed that its results were largely consistent with TBSS and parcellation-based analyses in the overall spatial pattern of effects, while also revealing additional spatially localized differences. These findings suggest that the parameterization provides a simple, computationally efficient, and spatially detailed approach for investigating midsagittal CC microstructure, offering a structure-specific complement to whole-brain and region-based methods.

RevDate: 2026-11-20
CmpDate: 2026-11-20

Song M, Liu A, Liang H, et al (2026)

Shared mechanisms and therapeutic horizons: exploring the potential interplay between benign prostatic hyperplasia/lower urinary tract symptoms and Alzheimer's disease.

Frontiers in neurology, 17:1817059.

Alzheimer's disease (AD) and benign prostatic hyperplasia (BPH) are two prevalent age-related disorders with significant global healthcare burdens. Traditionally viewed as distinct conditions, emerging evidence suggests that they may share common pathophysiological mechanisms, including chronic inflammation, endocrine dysregulation, metabolic dysfunction, cardiovascular impairment, and sleep disturbances. This review synthesizes current epidemiological, mechanistic, and therapeutic insights linking BPH and AD, with a focus on their overlapping risk factors and molecular pathways. Although most of the currently available evidence is observational and cannot establish causality, understanding these interactions could inform novel preventive and therapeutic strategies to mitigate the dual burden of neurodegenerative and urological conditions in older populations.

RevDate: 2026-11-20
CmpDate: 2026-11-20

Vasiliu O (2026)

Gene therapy and RNA-directed medicines in Alzheimer's disease: toward a precision framework for clinical translation.

Frontiers in aging neuroscience, 18:2011267.

BACKGROUND: Gene transfer and RNA-directed medicines offer distinct approaches to modifying disease-relevant biology in Alzheimer's disease (AD). Existing precision drug-development frameworks require adaptation to account for persistent expression, anatomical distribution, and platform-specific limits on dose adjustment.

OBJECTIVE: To propose a modality-specific framework organized around molecular target, biological subgroup, anatomical and cellular delivery, and disease stage, with common requirements for target engagement, clinically meaningful outcomes, and long-term safety.

METHODS: A targeted appraisal of selected clinical, translational, and registry sources was used to develop and illustrate the framework, without a systematic review or quantitative synthesis.

RESULTS: The retrieved clinical programs illustrate core domains of the suggested framework: nerve growth factor (NGF) studies showed persistent expression, but postmortem findings in three phase I participants revealed limitations in anatomical delivery; apolipoprotein E (APOE) ε2 gene addition in APOE ε4 homozygotes represents a genotype-directed intervention, whereas brain-derived neurotrophic factor delivery targets vulnerable memory circuits; tau-directed antisense oligonucleotides and RNA-interference approaches targeting tau or amyloid precursor protein expand the range of molecular targets and platforms. The conference-reported phase II CELIA trial findings, consisting of a missed primary dose-response endpoint despite biomarker reductions and exploratory secondary clinical findings, highlight why target engagement and efficacy require separate evaluation. When designing trials in this field, there must be explicitly defined relationships among mechanism, population, exposure, timing, and outcomes before interpreting results.

CONCLUSION: The proposed framework is in its early developmental phase, and its value depends on prospective evaluation, platform-appropriate measures of biological activity, as well as on reassessment of delivery assumptions and therapeutic mechanisms following negative findings.

RevDate: 2026-11-20
CmpDate: 2026-11-20

Khan L, Sahibdad I, Ullah N, et al (2026)

Neuroprotective and Neuroregenerative Effects of FGF-9 and Small Molecules Induced Neural Progenitor Cells in Chemically Induced Rat Model of Alzheimer's Disease.

Stem cells international, 2026:5123338.

Growth factors and small molecules are critical regulators of neural differentiation of stem cells, playing a pivotal role in modulating cellular signaling pathways that promote neurogenesis and enhance cell survival. Their combined application offers significant protective effects in Alzheimer's disease (AD) by facilitating the generation of neural progenitor cells (NPCs) capable of neuroprotection and regeneration in damaged neural tissues. This study aimed to generate NPCs from umbilical cord-derived mesenchymal stem cells (UC-MSCs) using small molecules CHIR99021, valproic acid (VPA), and fibroblast growth factor 9 (FGF-9) to evaluate their therapeutic efficacy in a rat model of neurodegeneration. Neural differentiation was induced in UC-MSCs using CHIR99021, VPA, and FGF-9 and assessed for minimal cytotoxicity and characterization through MTT assay, RT-PCR analysis, and immunocytochemistry. For in vivo studies, 25 healthy adult male albino Wistar rats were chemically induced with AlCl3 neurodegeneration. Treatment groups, including normal saline negative control, AlCl3 positive control, MSCs, neural induction media (NIM), CHIR + VPA, and CHIR + VPA + FGF-9 treated groups were assessed for behavioral assessments to evaluate cognitive and anxiety-related behaviors, followed by molecular and histopathological analysis of brain tissue. Gene expression analysis in NPCs treated with CHIR + VPA + FGF-9 demonstrated significant upregulation of neural progenitor genes: Nestin, Sox-2, and GFAP along with activation of key neurogenic signaling pathway markers Hes 1 and FGFr-3 with statistical significance (p < 0.001), respectively. The CHIR + VPA + FGF-9 induced NPCs exhibited elevated expression of neurotrophic factors NTF, BDNF, and GDNF (p < 0.001, respectively), supporting their neuroprotective and regenerative potential. Molecular analysis showed a decline in the expression of neurodegenerative pathological: MAPT-1 (p < 0.01) and inflammatory markers: NFkB (p < 0.05) and TNF-α (p < 0.01). Histological and immunohistochemical findings demonstrated reduced neuronal degeneration and enhanced neuronal survival in the hippocampus. Furthermore, protein expression of amyloid precursor protein (APP) was decreased (p < 0.001 vs. AlCl3) and cell proliferation marker (Ki67) was elevated (p < 0.001 vs. AlCl3) in NPCs-treated animals. These findings suggest that FGF-9, CHIR99021, and VPA-induced NPCs exert neuroprotective and neuroregenerative effects, highlighting their potential as a favorable therapeutic approach for AD.

RevDate: 2026-11-20
CmpDate: 2026-11-20

Xie Z, Lu Y, Qiu Y, et al (2026)

CD8[+] T cells drive neuroinflammation and cognitive decline in Alzheimer's disease.

Frontiers in immunology, 17:1990281.

Alzheimer's disease (AD) is the most common neurodegenerative disease in the world, and its pathogenesis is very complex, posing a serious threat to human health. The reciprocal regulation of the nervous and immune systems plays a key role in driving AD progression, although the specific mechanisms remain to be elucidated. In recent years, attention has increasingly focused on the role of adaptive immune cells in AD. Among them, CD8[+] T cells have been found to infiltrate the brain parenchyma of AD patients, and this phenomenon is closely associated with neuronal injury and cognitive decline. This review first outlines the epidemiology and pathomechanisms of AD and systematically summarizes CD8[+] T cell activation, cytotoxicity, migration, and function. It emphasizes the dual potential role of these cells in AD. These cells may exacerbate neuronal injury and cognitive dysfunction through multiple pathways, including direct cytotoxicity, release of pro-inflammatory cytokines, disruption of the blood-brain barrier, and inhibition of neuroplasticity. However, under specific microenvironmental conditions, CD8[+] T cells may also exert immunomodulatory functions and confer potential protective effects. This review also discusses related therapeutic strategies based on these mechanisms. Finally, we discuss the difficulties currently facing research and future directions for clinical translation. We believe that in-depth exploration of the immunoregulatory mechanisms of CD8[+] T cells in AD can provide theoretical foundations and new perspectives for developing innovative immunotherapies targeting neuroinflammation and cognitive impairment in AD.

RevDate: 2026-11-20

Shetty AK, PM Mandhyan (2026)

Aging and neurodegenerative diseases: emerging technologies and therapeutics.

Military Medical Research, 13(1):100079.

RevDate: 2026-11-20
CmpDate: 2026-11-20

Chen HW (2026)

Bypassing the Blood-Brain Barrier: A Dual-Axis Framework for Parkinson's Disease Utilizing Glymphatic-Lymphatic Clearance and In Situ Chaperone Synthesis.

Cureus, 18(10):e118265.

Parkinson's disease (PD) is characterized neuropathologically by loss of dopaminergic neurons in the substantia nigra pars compacta and by aggregation of misfolded alpha-synuclein into Lewy bodies and Lewy neurites, which is proposed to propagate in a prion-like manner following a stereotyped, stage-dependent pattern described by Braak staging. Because any circulating agent intended to act within the central nervous system (CNS) must cross the blood-brain barrier, this review proposes active craniospinal tensioning (ACT), a mechanical, non-pharmacological route to disease modification acting on cerebrospinal fluid (CSF) and cerebral venous pressure dynamics. ACT combines two concurrent mechanisms converging on a single venous-side target within Monro-Kellie/Queckenstedt pressure continuity: suboccipital venous occlusion-rebound, proposed to raise and release craniospinal CSF pressure to accelerate venous-side glymphatic efflux, and dural pull-recoil, a reverse Queckenstedt effect in which spinal elongation is proposed to generate a CSF-side pressure gradient with a coupled venous component. The proposed disease-modifying route is clearance of transiting extracellular alpha-synuclein from the perivascular and interstitial space before it templates a neighboring cell. The claim is scoped to the CNS phase of PD, excluding peripheral vagal or olfactory transport, with its most direct anatomical rationale at the dorsal motor nucleus of the vagus (DMV), one of the two earliest CNS sites of Lewy pathology in Braak staging and adjacent to ACT's craniocervical site of action, where ACT is proposed to act on onward extracellular spread rather than on arrival. A secondary, hypothesis-generating axis, cerebral venous preconditioning (CVPC), proposes that the same cycle produces venule- and capillary-wall strain sufficient to activate heat shock factor 1 (HSF-1) within the neurovascular unit, beginning at the vessel wall, independent of oxygen tension, with a possible contribution from hypoxia-inducible factor 1-alpha (HIF-1α) left open; the mechanical route alone is proposed as sufficient. Validation is staged, with diffusion tensor image analysis along the perivascular space (DTI-ALPS) and neuromelanin-sensitive magnetic resonance imaging with quantitative susceptibility mapping (QSM) of the substantia nigra as dual falsification endpoints over at least two years, and any disease-modification claim deferred to a randomized, delayed-start trial. This framework is entirely theoretical, requires clinical validation, and extends a dual-axis template already applied to Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS).

RevDate: 2026-11-20

Huang H, Chen S, Chen Y, et al (2026)

Association of cumulative cholesterol-HDL-glucose index with cognitive function changes and risk of new-onset mild cognitive impairment in middle-aged and older adults: A prospective cohort study.

Journal of Alzheimer's disease : JAD [Epub ahead of print].

BackgroundMetabolic dysfunction is a modifiable contributor to cognitive impairment and Alzheimer's disease risk. The cholesterol-HDL-glucose (CHG) index integrates atherogenic dyslipidemia and hyperglycemia, but the cognitive implications of cumulative CHG exposure are unknown.ObjectiveTo examine the association of cumulative CHG (cuCHG) exposure with cognitive trajectories and new-onset mild cognitive impairment (MCI).MethodsAdults aged ≥45 years were drawn from the China Health and Retirement Longitudinal Study (CHARLS, 2011-2020). MCI was defined using ageing-associated cognitive decline criteria. K-means clustering classified longitudinal CHG trajectories, and cuCHG was calculated as [(CHG2012 + CHG2015)/2] × time interval. Linear mixed-effects models assessed cognitive trajectories, and Cox regression with restricted cubic splines evaluated incident MCI risk.ResultsAmong 2646 participants, 404 (15.3%) developed MCI over 5 years. All cognitive domains declined significantly (global cognition β/year = -0.343, 95% CI -0.367 to -0.320; all p < 0.001), but no time × cuCHG interaction was detected (all p > 0.05). In fully adjusted Cox models, the middle-CHG cluster showed 21% lower MCI risk than the low-CHG cluster (HR = 0.79, 95% CI 0.62-0.99, p = 0.043); the high-CHG cluster did not differ. Restricted cubic splines showed a non-linear relationship (p for non-linearity < 0.05), with elevated risk at both extremes. A significant sex interaction was observed (p = 0.015).ConclusionsCumulative CHG exposure showed a non-linear association with incident MCI, with a middle-range trajectory independently associated with lower risk. Balanced metabolic homeostasis, rather than indiscriminately minimizing metabolic indices, may be relevant to cognitive ageing.

RevDate: 2026-11-20

Guo X, Liu Y, Wang Z, et al (2026)

Clinical value of plasma p-tau217 in identifying mild cognitive impairment due to Alzheimer's disease: A comparative multimarker analysis.

Journal of Alzheimer's disease : JAD [Epub ahead of print].

BackgroundAlzheimer's disease (AD) causes progressive neurodegeneration, and mild cognitive impairment due to AD (AD-MCI) represents a critical window for intervention. Invasive or costly diagnostic tools hinder early detection. The 2024 NIA-AA criteria recognize plasma p-tau217 as a core blood-based biomarker for prodromal AD, supporting the clinical translation of peripheral pathological markers.ObjectiveTo compare plasma biomarker profiles between AD-MCI and cognitively unimpaired (CU) participants, evaluate the diagnostic performance of p-tau217, p-tau181, and Aβ42/Aβ40 ratio for detecting this AD-MCI group, and assess correlations between these plasma biomarkers and cognitive function in the cohort.MethodsFifty-one participants were enrolled from a single center in China. Plasma p-tau217, p-tau181, and the Aβ42/Aβ40 ratio were measured using a domestically developed fluorescent magnetic-particle immunoassay (FMIA). ROC curve analysis was used to assess diagnostic performance, and Spearman correlation analysis was used to test biomarker-cognition associations.ResultsPlasma p-tau217 yielded the highest AUC = 0.923 (cut-off: 4.35 pg/mL; sensitivity 80.9%; specificity 96.6%), outperforming p-tau181 (AUC = 0.902) and the Aβ42/Aβ40 ratio (AUC = 0.714). Only weak, non-significant correlations were observed between biomarkers and cognitive scores in the AD-MCI group (r ranged from -0.22 to 0.05).ConclusionsPlasma p-tau217 measured using this FMIA showed excellent diagnostic performance for AD-MCI in a cohort from southwestern China. The population- and platform-specific cut-offs differed from those reported in Western cohorts using Simoa-based assays. Weak cognitive correlations suggest that plasma p-tau217 primarily reflects brain amyloid and tau pathology rather than cognitive severity, supporting its use for community-based triage screening for early AD.

RevDate: 2026-11-20

Merchant RA, Vellas B, J Woo (2026)

Intrinsic capacity and plasma p-tau217 among community-dwelling older adults: a cross-sectional analysis of the SPICE study.

The journals of gerontology. Series A, Biological sciences and medical sciences pii:9104167 [Epub ahead of print].

Plasma phosphorylated tau 217 (p-tau217) is a promising blood-based biomarker of Alzheimer's disease (AD) pathology, but its association with multidomain intrinsic capacity (IC) remains unclear. We examined associations between IC and plasma p-tau217 in community-dwelling older adults. This cross-sectional study included 200 community-dwelling participants aged ≥60 years. Cognitive, locomotor, psychological and vitality capacities were assessed using the Montreal Cognitive Assessment (MoCA), Short Physical Performance Battery (SPPB), Patient Health Questionnaire-9 (PHQ-9) and Mini Nutritional Assessment-Short Form (MNA-SF), respectively. Scores were rescaled to 0-100 and averaged to derive the IC composite. Plasma biomarkers were measured using the Olink Target 48 Neurodegeneration panel. Multivariable linear regression were adjusted for age, sex, BMI, education and multimorbidity. Mean age was 71.9 years and 74.0% were women. Median IC decreased across increasing p-tau217 tertiles (95.0, 93.5 and 90.5; p < 0.001). Standardised composite IC was inversely associated with ln(p-tau217) (B=-0.162; 95% CI -0.258 to -0.066; p = 0.001). Similar inverse associations were observed for cognitive, psychological and vitality capacities as well as gait speed (all p < 0.05). Each 10-point decrease in composite IC was associated with higher adjusted odds of belonging to the combined middle and highest p-tau217 tertiles (T2/T3) compared with the lowest tertile (T1) (aOR=2.11; 95% CI 1.13-3.98; p = 0.019). The association between composite IC and p-tau217 remained significant after separate adjustment for GFAP, NfL, BACE1 and the Aβ42/Aβ40 ratio. These findings suggest that the relationship between multidomain IC and plasma p-tau217 extends beyond cognition alone. Longitudinal studies are needed to determine its clinical and prognostic significance.

RevDate: 2026-11-20

Saini M, Hooda T, Khatri R, et al (2026)

Nefopam as a neuroprotective agent in Alzheimer's disease: network pharmacology, molecular docking, molecular dynamics simulations, and in vivo evaluation.

Naunyn-Schmiedeberg's archives of pharmacology [Epub ahead of print].

Alzheimer's disease (AD) remains a progressive neurodegenerative disorder marked by declining cognition, deteriorating memory, and behavioural abnormalities, with no disease-modifying therapy established despite decades of investigation. This study investigated whether nefopam - a non-opioid, centrally acting analgesic - could be repositioned as a neuroprotective agent against AD. An integrated strategy was adopted, combining network pharmacology, molecular docking, molecular dynamics (MD) simulation, and an in vivo assessment using a scopolamine-induced rat model. Eight crystal structures representing seven AD-relevant targets were selected for the computational work: MAOB (1GOS), OPRM1 (4DKL), GRIN1 (4KFQ), SLC6A3 (4M48), HTR2A (6A93 and 8ZMG), SLC6A4 (7LWD), and the GluN1/GluN2B NMDA receptor (3QEL). Docking was performed with Glide, binding free energies were estimated by MM-GBSA, and complexes were simulated for 100 ns with Desmond. Network pharmacology analysis revealed 90 shared targets between nefopam and AD-associated pathways, pointing toward a multi-target mode of action. Docking followed by MM-GBSA calculations indicated favourable binding of nefopam across the selected targets, with the most favourable MM-GBSA ΔG bind values observed for HTR2A (6A93; - 65.77 kcal/mol), GRIN1 (- 58.28 kcal/mol), HTR2A (8ZMG; - 58.13 kcal/mol), and SLC6A4 (- 57.65 kcal/mol). Subsequent MD simulations indicated stable binding behaviour for SLC6A3 (4M48), HTR2A (6A93), and SLC6A4 (7LWD); GRIN1 (4KFQ) and MAOB (1GOS) displayed moderate stability, whereas HTR2A (8ZMG) showed instability at the protein level despite the ligand remaining reasonably well retained. In the in vivo phase, nefopam produced a dose-dependent improvement in neurobehavioural outcomes across the different assessment points. Biochemical analysis further showed a marked decline in MDA levels together with a significant rise in SOD and CAT activity, reflecting a meaningful antioxidant response. These findings suggest that nefopam exerts neuroprotective, antioxidant, and cognition-improving effects in the scopolamine-induced model of cognitive impairment, possibly involving serotonergic, glutamatergic, and monoaminergic signalling routes. Additional in vitro, mechanistic, and clinical research is needed before its repurposing for AD can be therapeutically confirmed.

RevDate: 2026-11-20

Topal F, Ünver H, Topal M, et al (2026)

Design, synthesis, and biological evaluation of novel imidazolium-based derivatives as cholinesterase inhibitors: kinetic, molecular docking, and ADMET studies.

Naunyn-Schmiedeberg's archives of pharmacology [Epub ahead of print].

In this study, novel imidazolium-based derivatives (1a-1 l) that are cholinesterase inhibitors were synthesized as potential therapeutic agents for Alzheimer's disease (AD). Their structures were elucidated using 13C-NMR and 1 H-NMR techniques. The inhibitory effects on acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) of the derivatives were examined in vitro and in silico. Most of the synthesized derivatives exhibited higher inhibitory activity than the reference compound, with IC50 values ranging from 21.93 to 50.58 nM for AChE and from 78.75 to 133.27 nM for BChE. The corresponding KI values ranged from 3.72 ± 0.06 to 8.60 ± 0.57 nM for AChE and from 34.58 ± 0.36 to 250.68 ± 72.95 nM for BChE. Molecular docking analysis revealed that compound 1e displayed the highest docking score against BChE (- 8.933 kcal/mol), and compound 1a showed the highest Glide docking score toward AChE (- 12.151 kcal/mol). The in silico ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) profiles of two newly synthesized imidazolium-based compounds (1a and 1i) were evaluated and compared against tacrine, a well-known cholinesterase inhibitor used as a reference standard. The analysis reveals that both novel compounds demonstrate higher hepatotoxicity and nephrotoxicity profiles compared to tacrine, with compounds 1a additionally showing potentially favorable blood-brain barrier penetration, metabolic stability, and lower mutagenicity risk. These findings indicate that the derivatives may represent potential structural candidates for further investigation as cholinesterase inhibitors relevant to AD. Further studies involving comprehensive pharmacokinetic, in vivo efficacy, and toxicity evaluations are warranted to validate the therapeutic potential of these imidazolium-based derivatives as cholinesterase inhibitors.

RevDate: 2026-11-20
CmpDate: 2026-11-20

Bao J, Peng Q, Gong XK, et al (2026)

HIV-1 Vpr-Mediated GSK-3β SUMOylation Induces Tau Phosphorylation and Neurodegeneration.

Molecular neurobiology, 63(1):.

HIV-1-associated neurocognitive disorder (HAND) has emerged as a prevalent and debilitating neurological disorder. Analogous to Alzheimer's disease (AD), HAND manifests Tau hyper-phosphorylation and heightened activity of the tau kinase GSK-3β. Nonetheless, the exact underlying mechanism driving neurodegeneration in the context of HIV-1 infection remains elusive. In this study, we unveil that the HIV-1 accessory protein Vpr augments GSK-3β SUMOylation and exacerbates Tau hyper-phosphorylation. Notably, GSK-3β SUMOylation is essential for Vpr instigating Tau hyper-phosphorylation. Vpr enhances GSK-3β SUMOylation at K183 site, consequently bolstering its stability and enzymatic activity. Furthermore, we identify SIM (SUMO interacting motifs)- 2 within Vpr as the pivotal sequence responsible for promoting GSK-3β SUMOylation. Significantly, Vpr triggers GSK-3β SUMOylation, Tau hyper-phosphorylation, synaptic impairment, and cognitive deficits in a murine model, whereas Vpr bearing mutations in SIM2 proves to be ineffective. Consequently, our findings suggest that HIV-1 Vpr contributes to Tau hyper-phosphorylation potentially through enhancing GSK-3β SUMOylation at the K183 site. This provides novel insights into the mechanisms by which HIV-1 compromises the central nervous system, precipitating neurocognitive disorder.

RevDate: 2026-11-20
CmpDate: 2026-11-20

Kamel NM, Amin AH, Rabie MA, et al (2026)

Natural phytocompounds targeting tau protein: therapeutic potential in Alzheimer's disease.

The Journal of pharmacy and pharmacology, 78(11):.

OBJECTIVES: Alzheimer's disease (AD) is a major and growing neurodegenerative disorder characterized by progressive cognitive and functional decline. Accumulating evidence indicates that pathological tau is closely associated with disease progression and cognitive impairment, supporting tau-directed therapeutic strategies.

METHODS AND KEY FINDINGS: This review provides a tau-centered mechanistic and translational synthesis of structurally defined phytocompounds, integrating evidence on kinase/phosphatase regulation, tau post-translational modifications, aggregation and propagation, autophagy-mediated clearance, neuroinflammation, oxidative stress, mitochondrial dysfunction, gut-brain signaling, and epigenetic regulation. Unlike reviews that mainly catalogue natural products with anti-Alzheimer activity, we distinguish direct tau-related effects from broader neuroprotective actions and critically consider evidence from biochemical, computational, cellular, animal, and available clinical studies. Major translational barriers, including poor solubility, metabolic instability, limited bioavailability, and insufficient blood-brain barrier penetration, are also discussed, together with nanocarrier-based strategies developed to improve brain delivery. Natural phytocompounds, including flavonoids, polyphenols, stilbenes, terpenoids, and alkaloids, have shown potential to modulate tau-related pathology through multiple mechanisms.

CONCLUSIONS: By linking molecular mechanisms with experimental evidence and delivery considerations, this review highlights both the therapeutic promise and the remaining challenges of phytocompounds as modulators of tau pathology in AD.

RevDate: 2026-11-20
CmpDate: 2026-11-20

Herrera-Zamora JM, Monroy-Rodriguez J, Garcia-Mancilla J, et al (2026)

AI-Based Monitoring Devices for the Identification of Circadian Parameters as Digital Predictive Biomarkers of Neurodegenerative Diseases in Older Adults: Systematic Review.

JMIR aging, 9:e83031 pii:v9i1e83031.

BACKGROUND: Neurodegenerative diseases such as Alzheimer disease, Parkinson disease, and related dementias are a growing health burden among older adults. Circadian disruption is increasingly recognized as both a consequence and a potential early marker of neurodegenerative progression. Wearable sensing combined with AI enables continuous, noninvasive, and ecologically valid monitoring of circadian parameters as potential digital biomarkers.

OBJECTIVE: This systematic review synthesizes evidence on AI-enhanced wearable and objective sensing devices used to monitor circadian parameters in older and cognitively vulnerable adults and evaluates their potential as digital predictive biomarkers for neurodegenerative diseases.

METHODS: Following PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) 2020 guidelines, an original search of PubMed, Scopus, and JMIR journals (June 2025) yielded 12 studies, 7 of which met updated eligibility criteria on rescreening. A complementary search of PubMed, IEEE Xplore, and the ACM Digital Library (March 24, 2026) added 3 eligible studies and 3 sensitivity references (excluded records retained to delimit the corpus boundary). Two reviewers (JMH-Z and JM-R) independently assessed risk of bias with the Mixed Methods Appraisal Tool. Heterogeneous end points precluded meta-analysis; the narrative synthesis covered 4 prespecified domains: device class, circadian construct, AI and machine learning (ML) method family, and population and neurocognitive context.

RESULTS: The final corpus comprised 13 records (10 eligible studies and 3 sensitivity references) published from 2015 to 2025. Wrist actigraphy predominated, and samples ranged from community-dwelling older adults to nursing home residents with advanced dementia (n=16-7297). Circadian parameters included interdaily stability, intradaily variability, relative amplitude, midline estimating statistic of rhythm, acrophase, and circadian stimulus. AI/ML methods included supervised learning (random forests, gradient boosting, and regression models), unsupervised clustering, and algorithm development or validation; 7 studies applied deterministic algorithms without fitting a predictive model. Circadian fragmentation was associated with functional decline, dementia risk, and cognitive performance. Most studies were descriptive or observational with small, nondiverse samples; no AI model was externally validated, and no study followed an AI-specific reporting guideline.

CONCLUSIONS: AI-enhanced wearable devices show meaningful potential for noninvasive measurement of circadian disruption in older and cognitively vulnerable populations. Evidence certainty is moderate for actigraphy-derived fragmentation-function associations in institutional settings and low for predictive biomarker claims in community populations. From 6 recurring challenges along the sensing-to-biomarker pipeline, we propose a 4-layer reference architecture (sensing and acquisition, circadian parameter extraction, AI/ML inference, and a clinical and validation interface) with a layered validation pathway. Longitudinal, multisite validation studies using standardized circadian metrics, diverse populations, and explainable AI remain necessary before clinical deployment as neurodegenerative biomarkers.

RevDate: 2026-11-20

Schebesta J, Baillet M, Heinrich L, et al (2026)

Volume of the mammillary bodies and cognitive trajectories in preclinical Alzheimer's disease.

EBioMedicine, 134:106564 pii:S2352-3964(26)00448-2 [Epub ahead of print].

BACKGROUND: As part of the Papez circuit, the mammillary bodies (MB) play a key role in episodic memory, but their contribution to cognitive changes in preclinical Alzheimer's disease (AD) remains underexplored. Here, we investigated the associations between MB volume and cognitive decline in cognitively unimpaired older individuals, and whether these associations differed by Aβ status.

METHODS: We examined 228 cognitively unimpaired older participants from the Harvard Ageing Brain Study (mean age: 73.5 ± 8.0, 64% female, all CDR = 0) who underwent baseline MRI, [11]C-Pittsburgh Compound B (PiB) PET imaging and annual cognitive assessments. MB volume was quantified using the FastSurfer-HypVINN tool, and PiB status was derived from a neocortical aggregate. Cognition was assessed over up to 11 years using the Preclinical Alzheimer's Cognitive Composite 5 (PACC5), as well as a memory and executive function composite.

FINDINGS: At baseline, PiB+ participants with lower MB volume showed poorer cognitive performance on the PACC5 and on memory and executive function composites. Longitudinally, lower baseline MB volume was associated with steeper memory and PACC5 decline, particularly among PiB+ participants. Control analyses showed that associations between posterior hypothalamic volume and cognitive performance, at baseline and over time, did not differ by PiB status. Similarly, associations between hippocampal volume and baseline cognition did not differ by PiB status, but hippocampal volume was associated with cognitive decline, more strongly in PiB+ individuals.

INTERPRETATION: These findings indicate that lower MB volume was associated with poorer cognitive performance and steeper decline in PiB+ individuals, suggesting that MB volume may serve as an indicator of cognitive decline in preclinical AD.

FUNDING: National Institutes of Health, Alzheimer's Association.

RevDate: 2026-11-20

Valderrama D, Fourtoy A, Mähler I, et al (2026)

MultiNSDE: treatment-aware neural SDEs for generative modeling of real and counterfactual patient trajectories.

Journal of biomedical informatics pii:S1532-0464(26)00154-1 [Epub ahead of print].

BACKGROUND: Synthetic patient data may facilitate biomedical research, trial planning, and the construction of synthetic control arms, but there is a lack of methods that enable the realistic generation of mixed-type longitudinal clinical trial data while accounting for treatment effects.

METHODS: We developed MultiNSDE, a neural stochastic differential equation framework for modeling high-dimensional static and longitudinal clinical study data, including continuous, categorical, and time-to-event outcomes. The model separates treatment- and placebo-associated dynamics, enabling treatment-aware individual trajectory simulation and counterfactual treatment assignment.

RESULTS: MultiNSDE was evaluated on three neurodegenerative disease trial datasets: A4 in Alzheimer's disease, PRO-ACT in amyotrophic lateral sclerosis, and DATATOP in Parkinson's disease. The model reproduced static and longitudinal data distributions, extrapolated clinically plausible trajectories, and generated coherent counterfactual outcomes under treatment-to-placebo and placebo-to-treatment shifts. Synthetic data generated by MultiNSDE preserved average treatment effect estimates observed in the real datasets.

CONCLUSIONS: MultiNSDE provides a proof-of-concept for the generation of realistic mixed-type longitudinal clinical trial data while preserving clinically meaningful treatment-associated differences in outcomes. It may support disease modeling, counterfactual simulation, and synthetic control generation in neurodegenerative disease research.

RevDate: 2026-11-20

Chiba TJ, UR Desai (2026)

The Complex Contributions of Glycosaminoglycans in Alzheimer's Disease.

Matrix biology : journal of the International Society for Matrix Biology pii:S0945-053X(26)00113-7 [Epub ahead of print].

Alzheimer's Disease (AD) remains a formidable disease to treat and overcome. One reason for this is its complex etiology involving many proteins and mechanisms. The mechanisms underlying the formation, degradation and clearance of these proteins are moderately understood. Glycosaminoglycans (GAGs), key components of the extracellular matrix as well as cell surface proteoglycans, interact with AD proteins, including Aβ, tau, cathepsin D, BACE1, and apolipoprotein E, which have been implicated in many different aspects of AD pathogenesis. Interestingly, GAGs have been shown to have dual effects on proteases, e.g., cathepsin D, involved in both generation and degradation of Aβ. GAGs also impact tau phosphorylation and its uptake. HSPGs also act as molecular scaffolds to promote Aβ aggregation and prevent plaque degradation. Additionally, cell surface HSPGs bind to both ApoE and Aβ, enhance fibrillization, and impair clearance from the brain. Outside of these direct GAG-protein interactions, the anionic biopolymers are also known to influence growth factors and inflammatory mediators, which have indirect downstream effects in AD. Finally, GAG-rich perineuronal nets have been found to exhibit neuroprotective roles. This review brings together the complex contributions of GAGs in AD pathology. The review covers salient features of GAG-protein interactions, multiple AD hypotheses, direct effects of GAGs on AD proteins, insights gained from computational and retrospective clinical studies followed by a discussion on the future of GAGs or GAG-like molecules in the treatment of AD.

RevDate: 2026-11-20

Kim BS, Kim HS, Choe YM, et al (2026)

Estrogen loss and Alzheimer's disease: five exposures ordered by age, and why timing is the variable to test.

Frontiers in neuroendocrinology pii:S0091-3022(26)00071-3 [Epub ahead of print].

Alzheimer's disease occurs about twice as often in women as in men. A widely held hypothesis attributes part of the excess to loss of ovarian estradiol at menopause and, at its simplest, predicts that risk tracks the level of estrogen available to the brain. That prediction can be read against aromatase inhibitors, which engage brain aromatase and which millions of postmenopausal women take for years. We place this exposure alongside three other forms of estrogen loss - natural menopause, premenopausal oophorectomy and ovarian function suppression - and one receptor-level comparator, tamoxifen; order the five by age at exposure; and read them against the level-based model and its timing-modified form. Three randomized trials found no cognitive decrement with aromatase inhibition, and cohorts from four countries show no excess dementia during available follow-up (adjusted hazard ratio 1.04, 0.90-1.20, against no endocrine therapy). The ordering is difficult to reconcile with residual estrogen level as the operative variable (the lowest level carries no observed excess), weighs against abruptness (surgical and natural menopause did not differ in 233,802 women once age at menopause was adjusted), and is consistent with age: menopause before 40 carried a hazard ratio of 1.47, and in one breast-cancer cohort hormone-modulating therapy was associated with dementia at 0.48 at ages 65-69 and 2.39 at ≥90. The comparison is hypothesis-generating: current evidence does not support a simple monotonic model in which less estrogen means more disease; age at estrogen loss, and tissue state at that age, are the variables to test next.

RevDate: 2026-11-18

Ehret F, Fontanesi J, Wilson GD, et al (2026)

Low-dose, high hopes? The potential of radiation therapy in Alzheimer's disease.

RevDate: 2026-11-18

Hussain I, Ali A, Khan S, et al (2026)

Unraveling the Inhibitory Potential of Hydrazone Derivatives Against Cholinesterases: Molecular Interactions, Kinetic Behavior and Structural Features.

Archives of biochemistry and biophysics pii:S0003-9861(26)00336-X [Epub ahead of print].

Alzheimer's disease (AD) is a progressive neurodegenerative disorder associated with impaired cholinergic neurotransmission. Inhibition of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) represents an established approach to its symptomatic management. In this study, five pyridine-based Schiff base derivatives (3a-3e) were synthesized through the condensation of 2-((6-chloropyridin-2-yl)oxy)acetohydrazide with substituted aromatic aldehydes, affording the target compounds in 84-90% yields. Their structures were characterized using spectroscopic techniques, and their in vitro cholinesterase inhibitory activities were evaluated using galantamine as the reference inhibitor. Compound 3b exhibited the greatest inhibitory activity within the series against both AChE and BuChE, with IC50 values of 48.75 and 32.50 μM, respectively, although galantamine showed greater potency (40.30 and 28.88 mM, respectively). Molecular docking was subsequently performed to explore the potential binding orientations and interactions of the synthesized compounds with the selected cholinesterase targets. Overall, the experimental findings identify 3b as the most active derivative within this series, while the docking results provide complementary computational insights. Further experimental validation, including confirmation of inhibitory potency, enzyme kinetics, and cellular toxicity, is required to establish its biological potential. These findings provide a preliminary basis for further investigation of pyridine-based hydrazone derivatives as cholinesterase inhibitors.

RevDate: 2026-11-18
CmpDate: 2026-11-18

Xie W, Wang Y, Li L, et al (2026)

[Research progress on the neuro-endocrine-immune regulatory mechanism of acupuncture in the treatment of Alzheimer's disease].

Zhen ci yan jiu = Acupuncture research, 51(11):1553-1563.

Acupuncture can effectively improve cognitive function and delay disease progression in patients with Alzheimer's disease (AD). Studies have shown that acupuncture treatment for AD is closely related to the effective regulation of the neuro-endocrine-immune (NEI) network. This article reviews the NEI mechanism of acupuncture in the treatment of AD mainly from the following aspects: benign regulation of the nervous system--regulating levels of central neurotransmitters (cholinergic, monoaminergic, amino acid, neuropeptide) and their receptors, brain-derived neurotrophic factor levels, and regulation of neuronal cell cycle re-entry; regulation of the endocrine system--ameliorating hypothalamic-pituitary-adrenal axis dysfunction, regulating levels of related hormones (estrogen, testosterone) and insulin-like growth factor-1; regulation of the immune system--modulating activation of central neuroimmune cells (microglia, astrocytes) and homeostasis of the peripheral immune system, and regulating related inflammatory signaling pathways (such as Toll-like receptor 4/nuclear factor-κB, Janus kinase 2/signal transducer and activator of transcription 3, phosphatidylinositol 3-kinase/protein kinase B, etc.). This article aims to provide a basis for further exploring the mechanism and clinical applications of acupuncture in the treatment of AD.

RevDate: 2026-11-18

Chen P, Tao M, Han S, et al (2026)

Spontaneous Intermolecular Cross-Linking Produces Aβ Dimers With Multiple Alzheimer's Disease Relevant Activities.

Advanced science (Weinheim, Baden-Wurttemberg, Germany) [Epub ahead of print].

Despite success of therapies targeting the amyloid β-protein (Aβ), the molecular identity of the forms of Aβ which contribute to Alzheimer's disease (AD) remains poorly understood. SDS-stable Aβ dimers are present in higher-order aggregates and exert disease-relevant toxicity, but whether dimers form before or after large aggregates, or how dimers contribute to AD pathogenesis were previously unknown. Here, we report that covalently cross-linked Aβ1-42 dimers can form spontaneously upon prolonged incubation of Aβ fibrils and contain isopeptide bonds (Asp1-Glu22 and Asp1-Asp1), the same as those identified in dimers found in AD brain. Importantly, dimer-enriched Aβ aggregates (DEBA) are structurally distinct to dimer-poor aggregates (DPBA) and have enhanced resistance to proteolysis. Functionally, DEBA exhibit stronger binding to microglia, induce transcription of key pro-inflammatory cytokines, nucleate into plaque-like structures with microglia in vitro, and exacerbate amyloid deposition in App[NL-F/NL-F] mice. DEBA do not appear to be overtly neurotoxic, whereas solubilized DEBA induce toxicities reminiscent of that caused by Aβ-containing AD brain extract. These findings demonstrate prolonged incubation of fibrillar Aβ aggregates results in spontaneous formation of cross-linked dimers, and this is associated with changes in aggregate morphology and emergence of multiple disease-relevant activities.

RevDate: 2026-11-18

Nowrangi MA, Sharma A, Rosenberg PB, et al (2026)

Influence of Apathy on Financial Capacity: A Longitudinal Analysis of the ADNI Cohort.

The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry pii:S1064-7481(26)00569-5 [Epub ahead of print].

Apathy is the most prevalent neuropsychiatric symptom across the Alzheimer's disease (AD) spectrum, yet its relationship to financial capacity (FC) has not been systematically examined. We analyzed longitudinal data from 1,024 ADNI participants (575 cognitively normal, 353 mild cognitive impairment [MCI], 96 AD dementia) who completed 2,262 Financial Capacity Instrument-Short Form (FCI-SF) assessments, measuring apathy via a three-item GDS subscale (GDS-3) and the NPI-Q. Hierarchical linear mixed-effects models examined cross-sectional, lagged, trajectory, and cognitively-adjusted apathy-FC associations. Greater apathy predicted lower FCI-SF scores (GDS-3: β = -1.26; NPI-Q: β = -4.49, both p <0.001) and slower completion times (GDS-3: β = 10.89 sec; NPI-Q: β = 23.22 sec, both p <0.001), with effects most consistent in MCI. Informant-rated apathy at prior visits predicted subsequent decline in FCI-SF scores (β = -4.30) and completion time (β = 38.03 sec; both p <0.001). Baseline apathy and depression were associated with attenuated increases in completion time over follow-up, likely reflecting range restriction from elevated baseline values. Apathy associations persisted after controlling for executive, memory, and visuospatial performance, with depression showing similar but generally weaker effects. Apathy is a consistent, partially independent predictor of FC impairment across the AD spectrum, most pronounced in MCI and robust to cognitive adjustment. Both accuracy- and efficiency-based FC endpoints were affected, supporting completion time as a clinically meaningful outcome. Systematic assessment and treatment of apathy may help preserve financial independence in at-risk or affected older adults.

RevDate: 2026-11-18

Maqsood L, Azeem F, Zubair M, et al (2026)

Differential Expression and Therapeutic Targeting of K[+] Channels in Neurological Disorders: An Integrative Approach.

Omics : a journal of integrative biology [Epub ahead of print].

Potassium (K[+]) channels regulate cellular homeostasis and electrical signaling, particularly in the nervous system, and their dysfunction is linked to neurological disorders such as epilepsy, Alzheimer's disease (AD), and Parkinson's disease (PD). In this study, Gene Expression Omnibus (GEO) datasets (GSE252132, GSE190451, and GSE160299) were analyzed using GEO2R to identify differentially expressed K[+] channel genes. A total of 2741, 3681, and 861 differentially expressed genes were identified in AD, epilepsy, and PD, respectively, including the common K[+] channel genes KCNJ5, KCNJ6, and KCNJ12. Functional enrichment using Enrichr highlighted potassium ion transport, potassium channel complexes, voltage-gated potassium channel activity, and gonadotropin-releasing hormone secretion. STRING and Cytoscape-based protein-protein interaction and Molecular Complex Detection analyses identified 13 hub genes, including KCNJ6, KCNJ5, and KCNJ12. miRNet analysis identified 12 miRNAs, 1 transcription factor, and 7 target genes, with hsa-miR-138-5p predicted to regulate KCNJ6. Virtual screening of 2315 Food and Drug Administration-approved drugs and 2390 Traditional Chinese Medicine compounds identified Sorafenib, Hinokiflavone, Posaconazole, and 1,3,6-Tri-O-galloyl-beta-D-glucose as promising KCNJ6-binding candidates. These findings highlight K[+] channels, particularly KCNJ6, as biomarkers and therapeutic targets in neurological disorders.

RevDate: 2026-11-18
CmpDate: 2026-11-18

Hoagey DA, McKay NS, Joseph-Mathurin N, et al (2026)

Exploring healthy aging through preclinical Alzheimer disease in the Knight Alzheimer Research Imaging dataset.

Nature communications, 17(1):.

Alzheimer disease (AD) remains a significant global public health challenge, requiring robust multimodal datasets to elucidate its prolonged preclinical phase, improve early detection, advance understanding of disease trajectories, and guide intervention strategies. Here we present the Knight Alzheimer Research Imaging (KARI) dataset, established by the Washington University Knight ADRC to address this critical need. We detail comprehensive multimodal neuroimaging from 1,645 participants (aged 42-97) across 6,217 acquisitions. Spanning the AD spectrum from healthy aging to symptomatic disease, the cohort undergoes extensive longitudinal imaging using structural and functional magnetic resonance imaging (MRI) alongside positron emission tomography (PET) tracers for amyloid and tau pathology. This is complemented by rich clinical, cognitive, genetic, and biomarker data. In addition to raw imaging, the dataset provides quality-controlled processed outputs, including anatomical segmentations and biomarker quantification. By making this data accessible to researchers, the Knight ADRC aims to accelerate discoveries in pathophysiology, biomarker identification, and therapeutic development.

RevDate: 2026-11-18
CmpDate: 2026-11-18

Yim S, Lee EH, Lee J, et al (2026)

Plasma eMTBR-tau243 and p-tau205 as T2 biomarkers for biological staging and prognosis in Alzheimer's disease.

Nature communications, 17(1):.

Plasma biomarkers that reflect distinct stages of Alzheimer's disease (AD) could enable scalable biological staging. We evaluated phosphorylated tau (p-tau) species across multiple analytical platforms and the endogenously cleaved microtubule-binding region containing residue 243 (eMTBR-tau243) using a dedicated LC-MS/MS platform in a well-characterized cohort with amyloid PET and a subset with tau PET. While T1 biomarkers increased during preclinical stages, eMTBR-tau243 and p-tau205 increased later, consistent with fibrillar tau aggregation. eMTBR-tau243 showed the strongest and stage-dependent associations with regional tau PET and cognition, outperforming T1 biomarkers in predicting cross-sectional and longitudinal cognition. A plasma-based tau staging system integrating p-tau217 and eMTBR-tau243 closely aligned with PET-based tau staging and predicted longitudinal cognitive trajectories. These findings support plasma eMTBR-tau243 as a prototypical T2 biomarker and highlight the potential of plasma-based tau staging for prognosis and therapeutic decision-making in AD.

RevDate: 2026-11-18
CmpDate: 2026-11-18

Song C, Yao W, Hu X, et al (2026)

Stenotrophomonas maltophilia alleviates Alzheimer's disease model phenotype by inhibiting Aβ aggregation via autophagy.

NPJ biofilms and microbiomes, 12(1):.

Probiotics exert neuroprotective effects against Alzheimer's disease (AD) through modulation of gut-brain axis signaling pathways, yet disease-modifying therapies remain elusive. In this study, we demonstrate that Stenotrophomonas maltophilia (S. maltophilia) ameliorates AD-associated pathological and behavioral phenotypes in Caenorhabditis elegans (C. elegans) models, including learning deficits and paralysis. Mechanistically, S. maltophilia suppresses β-amyloid (Aβ) peptide aggregation by orchestrating the activation of conserved cellular pathways: autophagy, innate immune signaling, and unfolded protein responses in the mitochondria (UPRmt) and endoplasmic reticulum (UPRer). Specifically, S. maltophilia induces UPRmt in an atfs-1-dependent manner and activates UPRer via the PERK kinase PEK-1. Further mechanistic analysis suggests that S. maltophilia initiates a signaling cascade: activation of ATF-7 immune pathways enhanced autophagy and subsequent clearance of Aβ aggregates. Metabolomic screening further pinpointed pizotifen as a bioactive metabolite that might inhibit Aβ aggregation through immune modulation.

RevDate: 2026-11-18
CmpDate: 2026-11-18

Liu X, Luo L, Pritschet L, et al (2026)

Early menopause is associated with reduced global brain activity.

npj aging, 12(1):.

Menopause affects the aging process in women through a significant decline in ovarian hormone production in midlife. Women who experience early menopause show accelerated physiological aging, poorer memory, and increased risk of neurodegenerative diseases. However, how menopause timing affects brain activity remains unclear, which could be crucial for understanding early menopause-related aging acceleration and increased risk of dementia. Recent studies have revealed a highly structured infra-slow (<0.1 Hz) global brain activity and linked it to arousal and memory functions, as well as waste clearance in Alzheimer's disease (AD). Here, we examined how this global brain activity relates to age at menopause using resting-state fMRI data from the Human Connectome Project-Aging dataset. We found that women with earlier menopause (mean menopausal age 45 ± 3.5 yr) exhibited weaker global brain activity with reduced coupling to cerebrospinal fluid (CSF) flow compared to age-matched later-menopausal women (mean menopausal age 54 ± 1.2 yr). Differences appeared mainly in higher-order brain regions, where activation levels correlated with memory performance in earlier but not in intermediate or later menopausal women. These findings highlight brain activity changes linked to early menopause, suggesting a potential mechanism underlying memory decline and the increased risk of AD and dementias in early-onset menopausal women.

RevDate: 2026-11-18
CmpDate: 2026-11-18

Llorente-Saguer I, Arber C, NP Oxtoby (2026)

Theta: a multivariate normative statistic applied to amyloid β panel data in familial Alzheimer's disease.

NPJ systems biology and applications, 12(1):.

Biomarker ratios often outperform individual biomarkers in complex, multifactorial diseases. In Alzheimer's disease, bivariate ratios may fail to capture the complex stoichiometry of amyloid β (Aβ) processing. We extended the ratio concept into a multivariate framework and performed experiments on Aβ peptide data from four familial Alzheimer's disease cohorts (8 controls, 223 PSEN1 mutation carriers). We define "theta" as a multivariate statistic quantifying the angular divergence of each subject's peptide profile from a homeostatic norm. Performance was benchmarked against established Aβ ratios using AUC and precision-recall AUC. Theta consistently outperformed benchmarks across datasets, achieving near-perfect discrimination (AUC 0.999, PR AUC 0.964). Established ratios like Aβ42/40 and Aβ37/42 showed markedly lower precision-recall performance (0.201-0.410). Pairwise comparisons confirmed theta's superiority. Theta leverages the full multi-peptide Aβ profile, treating it as a unified geometric entity in the spirit of systems-level thinking, addressing the inherent limitations of simple pairwise ratios. Its consistent performance across diverse PSEN1 mutations underscores its robustness and suggests utility for early and precise detection of pathogenic shifts. Additional validation in human biospecimens is needed, and the framework may extend to sporadic Alzheimer's disease and broader multivariate modelling challenges such as differential diagnosis.

RevDate: 2026-11-18

Warmenhoven N, Binette AP, Collij LE, et al (2026)

Comparing plasma p-tau217 and plasma p-tau217/Aβ42 with CSF biomarkers for assessing Alzheimer's disease pathology.

Nature aging [Epub ahead of print].

Plasma biomarkers for Alzheimer's disease (AD) on fully automated platforms offer accessible, cost-effective diagnostic tools. Here we aimed to compare Lumipulse plasma phospho-tau217 (p-tau217) and the p-tau217/beta-amyloid42 ratio (p-tau217/Aβ42) with regulatory-authorized cerebrospinal fluid (CSF) biomarkers (Aβ42/Aβ40 and p-tau181/Aβ42) for identifying AD pathology (Aβ-PET visual read) across a memory clinic (n = 129), a primary care (n = 220) and a research cohort (n = 165). Regulatory-authorized cutoffs were used for the plasma and CSF biomarkers. Plasma biomarkers identified Aβ pathology with areas under the curve between 0.90 and 0.96. Using one cutoff, plasma p-tau217 (83-91%) and p-tau217/Aβ42 (83-92%) had comparable accuracies to CSF (88-90%) across all cohorts (all P ≥ 0.05). With a two-cutoff approach, plasma p-tau217 (90-97%) remained comparable to CSF (91%) in the clinical cohorts (all Padj ≥ 0.12). Results with cohort-derived cutoffs are also provided. In conclusion, regulatory-authorized plasma p-tau217 and p-tau217/Aβ42 demonstrated performance comparable to regulatory-authorized CSF tests for detecting Aβ pathology in symptomatic individuals.

RevDate: 2026-11-18
CmpDate: 2026-11-18

Dan T, Huang X, Ding J, et al (2026)

Understanding mechanistic role of structural and functional connectivity in tau propagation through multilayer modeling.

NPJ digital medicine, 9(1):.

Emerging neuroimaging evidence shows that pathological tau proteins build up along specific brain networks, suggesting that large-scale network architecture plays a key role in the progression of Alzheimer's disease (AD). However, how the interaction between structural (SC) and functional connectivity (FC) is associated with tau propagation remains largely unexplored. Using longitudinal neuroimaging data, we develop a multi-layer graph diffusion model to investigate this interplay. We identify a regionally asymmetric pattern, FC dominates tau accumulation in subcortical, insular, and frontotemporal regions, whereas SC prevails in occipital, parietal, and limbic areas. The principal conduit of tau propagation shifts from FC-mediated spread in early stages to SC-constrained diffusion as the disease advances. Furthermore, these propagation patterns correlate with regional expression of AD-associated genes (e.g., CHUK, TMEM106B, MCL1, NOTCH1, TH) and are selectively modulated by risk factors like APOE genotype and biological sex. By disentangling these dynamic pathways, our framework enables personalized trajectory prediction and refined patient stratification. These findings offer mechanistic insights into selective regional vulnerability, providing a quantitative basis for stage-specific therapeutic targeting and the optimization of clinical trial designs through network-based biomarkers. Our results are validated in an independent cohort, yielding consistent findings.

▼ ▼ LOAD NEXT 100 CITATIONS

RJR Experience and Expertise

Researcher

Robbins holds BS, MS, and PhD degrees in the life sciences. He served as a tenured faculty member in the Zoology and Biological Science departments at Michigan State University. He is currently exploring the intersection between genomics, microbial ecology, and biodiversity — an area that promises to transform our understanding of the biosphere.

Educator

Robbins has extensive experience in college-level education: At MSU he taught introductory biology, genetics, and population genetics. At JHU, he was an instructor for a special course on biological database design. At FHCRC, he team-taught a graduate-level course on the history of genetics. At Bellevue College he taught medical informatics.

Administrator

Robbins has been involved in science administration at both the federal and the institutional levels. At NSF he was a program officer for database activities in the life sciences, at DOE he was a program officer for information infrastructure in the human genome project. At the Fred Hutchinson Cancer Research Center, he served as a vice president for fifteen years.

Technologist

Robbins has been involved with information technology since writing his first Fortran program as a college student. At NSF he was the first program officer for database activities in the life sciences. At JHU he held an appointment in the CS department and served as director of the informatics core for the Genome Data Base. At the FHCRC he was VP for Information Technology.

Publisher

While still at Michigan State, Robbins started his first publishing venture, founding a small company that addressed the short-run publishing needs of instructors in very large undergraduate classes. For more than 20 years, Robbins has been operating The Electronic Scholarly Publishing Project, a web site dedicated to the digital publishing of critical works in science, especially classical genetics.

Speaker

Robbins is well-known for his speaking abilities and is often called upon to provide keynote or plenary addresses at international meetings. For example, in July, 2012, he gave a well-received keynote address at the Global Biodiversity Informatics Congress, sponsored by GBIF and held in Copenhagen. The slides from that talk can be seen HERE.

Facilitator

Robbins is a skilled meeting facilitator. He prefers a participatory approach, with part of the meeting involving dynamic breakout groups, created by the participants in real time: (1) individuals propose breakout groups; (2) everyone signs up for one (or more) groups; (3) the groups with the most interested parties then meet, with reports from each group presented and discussed in a subsequent plenary session.

Designer

Robbins has been engaged with photography and design since the 1960s, when he worked for a professional photography laboratory. He now prefers digital photography and tools for their precision and reproducibility. He designed his first web site more than 20 years ago and he personally designed and implemented this web site. He engages in graphic design as a hobby.

963 Red Tail Lane
Bellingham, WA 98226

206-300-3443

E-mail: RJR8222@gmail.com

Collection of publications by R J Robbins

Reprints and preprints of publications, slide presentations, instructional materials, and data compilations written or prepared by Robert Robbins. Most papers deal with computational biology, genome informatics, using information technology to support biomedical research, and related matters.

Research Gate page for R J Robbins

ResearchGate is a social networking site for scientists and researchers to share papers, ask and answer questions, and find collaborators. According to a study by Nature and an article in Times Higher Education , it is the largest academic social network in terms of active users.

Curriculum Vitae for R J Robbins

short personal version

Curriculum Vitae for R J Robbins

long standard version

RJR Picks from Around the Web (updated 11 MAY 2018 )